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Summary: Lafora disease (LD) is a fatal childhood epilepsy caused by recessive mutations in 
either the EPM2A or EPM2B gene. A hallmark of LD is the intracellular accumulation of 
insoluble polysaccharide deposits known as Lafora bodies (LBs) in the brain and other tissues. In 
LD mouse models, genetic reduction of glycogen synthesis eliminates LB formation and rescues 
the neurological phenotype. Therefore LBs have become a therapeutic target for ameliorating 
LD. Herein, we demonstrate that human pancreatic α-amylase degrades LBs. We fused this 
amylase to a cell-penetrating antibody fragment, and this antibody-enzyme fusion (VAL-0417) 
degrades LBs in vitro and dramatically reduces LB loads in vivo in Epm2a-/- mice. Using 
metabolomics and multivariate analysis we demonstrate that VAL-0417 treatment of Epm2a-/- 
mice reverses the metabolic phenotype to a wild-type profile. VAL-0417 is a promising drug for 
the treatment of LD and a putative precision therapy platform for intractable epilepsy.  
 
Introduction 
The progressive myoclonic epilepsies (PMEs) are a group of inherited disorders characterized by 
recurrent seizures, myoclonus, and progressive neurological decline. There are currently no 
treatments for PMEs, and anti-epilepsy drugs are palliative at best (Shahwan et al., 2005). Lafora 
disease (LD; epilepsy, progressive myoclonus type 2, EPM2) is a severe form of PME that 
typically manifests with tonic-clonic seizures and myoclonic jerks in the early teen years 
followed by rapid neurological deterioration, increasingly severe and frequent epileptic episodes, 
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dementia and death within ten years of onset (OMIM: 254780). LD is caused by mutations in the 
EPM2A or EPM2B genes that encode laforin, a glycogen phosphatase, and malin, an E3 
ubiquitin ligase that ubiquitinates enzymes involved in glycogen metabolism (reviewed in 
(Gentry et al., 2018)). LD is distinguishable from other PMEs by the presence of cytosolic 
polysaccharide inclusions known as Lafora bodies (LBs) most notably in the brain, where they 
are found in neuronal cell bodies dendrites, and astrocytic processes, and in other tissues such as 
muscle, heart, and liver. Among the PMEs, LD is uniquely considered a glycogen storage disease 
(GSD).  Independent studies from multiple groups demonstrated that Epm2a-/- and Epm2b-/- 
mice, similar to LD patients, develop LBs and exhibit neurodegeneration, neurological 
impairments, and increased susceptibility to seizures (Criado et al., 2012; DePaoli-Roach et al., 
2010; Duran et al., 2014; Ganesh et al., 2002; Garcia-Cabrero et al., 2012; Garcia-Cabrero et al., 
2014; Tiberia et al., 2012; Valles-Ortega et al., 2011). 
 Glycogen and starch are the major carbohydrate storage molecules in mammals and plants, 
respectively (Brewer and Gentry, in press). Mammalian glycogen, LBs, and starch are all 
glucose polymers (i.e. polysaccharides) composed of α-1,4-linked linear chains of glucose and α-
1,6 linked branch points, but they have different properties. Glycogen consists of linear chains of 
~13 glucose units that each give rise to two branches, producing a highly water-soluble molecule 
with a maximum diameter of 42 nm (Graham et al., 2010). LBs, which form in the absence of 
functional laforin or malin, are comprised of abnormal polysaccharide referred to as 
polyglucosan. The term polyglucosan refers to any glucose polymer that is abnormal, and other 
types of polyglucosan bodies have been described in some GSDs (Cavanagh, 1999). Unlike 
glycogen, LBs are water-insoluble, hyperphosphorylated, contain long glucose chains, and range 
in size from a few microns to up to 35 or 40 μm (Nitschke et al., 2013; Sakai et al., 1970; 
Tagliabracci et al., 2008; Yokoi et al., 1968). Dr. Gonzalo Rodriguez Lafora first described these 
inclusions in patient autopsies, noting their histochemical similarity to plant starch (Lafora, 
1911). Decades later Sakai and colleagues isolated these inclusions from patient tissue and 
showed that LBs are indeed structurally more similar to starch than to glycogen (Sakai et al., 
1970; Yokoi et al., 1968). Plant starch is composed of infrequently branched, longer glucose 
chains that exclude water and allow for much larger, more energy-dense molecules to form (up 
to 100 μm in diameter) (Ball et al., 2011; Emanuelle et al., 2016; Tester et al., 2004). Plant starch 
and LBs both contain significantly more covalently bound phosphate and longer glucan chains 
than mammalian glycogen (DePaoli-Roach et al., 2015; Gentry et al., 2009; Sakai et al., 1970). 
Loss of laforin or malin function results in the transformation of glycogen molecules into 
hyperphosphorylated polyglucosan molecules with an altered chain length distribution, and these 
aberrant molecules, prone to precipitation, accumulate to form LBs (Sullivan et al., 2017). How 
laforin and malin prevent this process is still being defined.  
  Reactive astrocytes and activated microglia upregulated in aged Epm2a-/- and Epm2b-/- 
mice, particularly in the hippocampus (Duran et al., 2014; López-González et al., 2017; Sanchez-
Elexpuru et al., 2017; Turnbull et al., 2011). These glial markers are used to measure 
neurodegeneration in these models. Results from multiple labs have established that 
accumulation of polyglucosan drives this gliosis in both LD and non-LD models. Glycogen 
synthase is the only mammalian enzyme able to catalyze glucose polymerization in vivo. Epm2b-
/- mice lacking glycogen synthase (Gys1) in the brain are devoid of cerebral glycogen and LBs, 
exhibit no gliosis, and have normal electrophysiology (Duran et al., 2014). A similar phenotypic 
rescue was observed when Gys1-/- mice were crossed with Epm2a-/- mice (Pederson et al., 
2013). Furthermore, Epm2b-/- mice lacking just one Gys1 allele in the brain have reduced 
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glycogen and also show near complete rescue of these phenotypes (Duran et al., 2014). Epm2a-/- 
and Epm2b-/- mice lacking Protein Targeting to Glycogen (PTG), a protein that promotes 
glycogen synthesis, also exhibit reduced LB accumulation, and neurodegeneration and 
myoclonic epilepsy are resolved in these animals (Turnbull et al., 2011; Turnbull et al., 2014). 
These results demonstrate that decreased or complete absence of the glycogen synthesis 
machinery ablates LB formation and neurodegeneration in LD mouse models. The reverse has 
also been observed: overexpression of a constitutively active form of glycogen synthase in 
otherwise wild type animals drives neurodegeneration in both flies and mice (Duran et al., 2012). 
The accumulating polysaccharide in transgenic animals overexpressing glycogen synthase is a 
polyglucosan (i.e. abnormal) rather than normal glycogen (Raben et al., 2001). Collectively, the 
aforementioned studies demonstrate that cerebral LB accumulation is pathogenic. These studies 
have both elucidated the molecular etiology of LD and have made LBs an obvious therapeutic 
target. 
 Efforts to develop a targeted therapy (i.e. precision medicine) for LD are ongoing (Brewer 
and Gentry, 2018; Brewer et al., 2019). One form of precision medicine that has been utilized for 
treating GSDs is the introduction of exogenous replacement enzymes. Enzyme replacement 
therapy has proven effective for Pompe disease (OMIM: 232300), an inherited GSD (van der 
Ploeg et al., 2010). Pompe patients are deficient in the lysosomal enzyme that degrades 
glycogen, acid α-glucosidase (GAA), and are currently treated with a recombinant human form 
of this protein known as rhGAA or alglucosidase alfa (Myozyme®, Lumizyme®, Genzyme) 
(Kishnani et al., 2007; van der Ploeg et al., 2010). The uptake of rhGAA is a receptor-mediated 
endocytic process that targets rhGAA to the lysosome. However, there is a significant portion of 
cytosolic glycogen in Pompe patients, and since rhGAA only targets lysosomal glycogen, those 
with large pools of cytoplasmic glycogen do not respond well to the current therapy (Thurberg et 
al., 2006). In LD, LBs are entirely cytosolic. Histological studies from patient tissues report that 
LBs are not membrane bound, and this observation has been confirmed in mouse models 
(Berard-Badier et al., 1980; Criado et al., 2012; Ishihara et al., 1987; Van Hoof and Hageman-
Bal, 1967). Thus, a therapeutic enzyme degrading LBs must be delivered to the cytosol.  
 Although cytosolic targets remain challenging for protein therapeutics, antibody-based 
delivery platforms provide a means for penetrating the cell membrane (reviewed by (Rehman et 
al., 2016)). The monoclonal anti-DNA autoantibody 3E10 and its antigen-binding (Fab) and 
variable domain (Fv) fragments can be fused to an enzyme to facilitate cytosolic delivery in 
multiple cell types (Hansen et al., 2006; Hansen et al., 2005; Weisbart et al., 1998). This 
antibody-enzyme fusion (AEF) strategy has proven successful for the replacement of a cytosolic 
enzyme and rescue of X-linked myotubular myopathy in mice (Lawlor et al., 2013). A Fab-GAA 
fusion has similar efficacy to reduce glycogen in Pompe mice with the additional advantage of 
targeting both lysosomal and cytosolic glycogen and is now in Phase 1/2 clinical trials (Valerion 
Therapeutics, 2016; Yi et al., 2017). Rather than utilizing the AEF platform to deliver a 
replacement enzyme, we generated an AEF designed to penetrate cells and degrade pathogenic 
LBs. We show that an AEF comprised of the humanized 3E10 Fab fragment and pancreatic α-
amylase degrades LBs in vitro, degrades glycogen and polyglucosan in situ, and reduces LB load 
in vivo. Furthermore, we utilize a metabolomics approach to demonstrate that the drug reverses 
the physiological effects of LB accumulation. 
 
Results  
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Construction of an antibody-enzyme fusion (AEF) that degrades starch 
An important consideration in designing an LB-degrading enzyme is that LBs are less sensitive 
to enzymatic hydrolysis than normal glycogen. Resistance to digestion with diastase (a generic 
term for enzymes that degrade polysaccharides) is a defining feature of LBs and one factor that 
differentiates LBs from glycogen (Girard et al., 2013; Van Hoof and Hageman-Bal, 1967). 
However, in routine histological preparations, embedded sections are only incubated with 
diastase for 15-30 minutes prior to staining. Early studies reported that LBs in tissue sections can 
be digested by a 5-10 hour incubation with pancreatic α-amylase and γ-amylase (i.e. 
amyloglucosidase), but they are somewhat resistant to digestion by β-amylase or glycogen 
phosphorylase (Nikaido et al., 1971; Sakai et al., 1970; Yokoi et al., 1968).  
 Another consideration in the AEF design is the biochemical structure of the target LBs 
themselves. Glycogen, starch, and LBs are all polysaccharides with different properties. LBs are 
considered more similar to starch than glycogen due to their insolubility, elevated phosphate 
levels, and the increased chain length of their constituent glucose chains. We hypothesized that 
starch could serve as a proxy for LBs in a screen to identify a candidate therapeutic enzyme. We 
screened a panel of amylases to determine which possessed robust activity against starch, and 
therefore would likely degrade LBs. We found that only α-amylases showed significant activity, 
and pancreatic α-amylase had the highest capacity to degrade starch (Fig. 1A). Pancreatic α-
amylase is naturally secreted by the human pancreas for digestion of carbohydrates in the gut, 
cleaving α-1,4 linkages to yield maltose, maltotriose and low molecular weight oligosaccharides. 
It has previously been shown to digest LBs in tissue sections (Nikaido et al., 1971). Thus, 
pancreatic α-amylase is a putative candidate for degrading LBs.  
 An AEF designated as VAL-0417 was generated by fusing the humanized 3E10 IgG1 Fab 
heavy chain fragment with human pancreatic α-amylase and then coexpressed in HEK293-6E 
cells with the corresponding light chain as a secreted heterodimer (Fig. 1B). The fusion was 
purified from HEK293-6E cell conditioned media by affinity chromatography, and the purity 
was determined by reducing and nonreducing SDS-PAGE (Fig. 1C). The addition of β-
mercaptoethanol (BME) dissociated the heavy and light chains, producing two distinct bands of 
75 and 25 kDa. In the absence of BME, only a single band was observed at 100 kDa, 
corresponding to the intact Fab-amylase fusion. The specific activity of an α-amylase was then 
tested using a substrate that consists of seven glucose moieties and a chromophoric para-
nitrophenyl moiety that is capped with an ethylidine group to block the action of other hydrolytic 
enzymes (Fig. 1D) (Kruse-Jarres et al., 1989). Using this substrate, the specific activity of VAL-
0417 was determined to be 10.5 units/mg.  
 VAL-0417 activity was then tested against plant starch. After a 2-hour incubation, VAL-
0417 degraded starch in a dose-dependent manner: 5 μg of enzyme released 61 μg of soluble 
glucan product (Fig. 1E). We employed scanning electron microscopy (SEM) to visualize the 
effects of degradation on the starch granules. In the absence of enzymes, starch granules had a 
smooth, polyhedral or subspherical appearance (Fig. 1F). Overnight treatment with VAL-0417 
produced cavities in the granule surface, representing areas of active hydrolysis, and numerous 
partially degraded granules were visible (Fig. 1F). When the ratio of VAL-4017 to starch was 
reduced by 10-fold, amylolysis was less extensive: fewer partially degraded particles were 
visible and most granules were only decorated with small pits (Fig. S1). Other groups have 
observed similar "pitting" of starch granules with α-amylase and other amylolytic enzymes (Jung 
et al., 2017; Sujka, 2007).  
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Isolation and characterization of LBs from LD mice 
Polysaccharides (both glycogen and LBs) are typically purified from Epm2a-/- and Epm2b-/- 
mice based on a method described by Pflüger in 1909 where the tissue is heated in strong KOH 
and the glycogen is precipitated with alcohol (Good, 1933; Pflüger, 1909). The isolated particles 
are 15-65 nm in size when visualized by transmission electron microscopy (Tagliabracci et al., 
2008), orders of magnitude smaller than the intact LBs observed in fixed tissue sections, and the 
method does not separate LBs from glycogen. It is well-established that heating changes the 
physiochemical properties of starch, leads to granule swelling, and enhances its sensitivity to 
enzymatic degradation (Kulp, 1981). Therefore, it is likely that this protocol disrupts the native 
structure of LBs, intermixing the individual polyglucosan constituents of LBs with normal 
glycogen molecules. We developed a procedure for isolating pure and native LBs from tissue so 
that we could test the sensitivity of LBs to VAL-0417 degradation. 
 A study from the 1960s showed that native LBs could be isolated from patient brain tissue by 
centrifugation steps and successive treatments with proteolytic enzymes (Yokoi et al., 1968). We 
designed a similar method for isolating native LBs from the brain, heart and skeletal muscle of 
Epm2a-/- mice (Fig. 2A, see STAR Methods). Our procedure separates soluble glycogen 
(present in the supernatant) from the insoluble LBs (Fig. S2, see STAR Methods). Final LB 
yields from each tissue type corresponded to ~30% of the total polysaccharide detected in the 
original tissue homogenate (Fig. 2B and C). Phosphate content of the final LBs from skeletal 
muscle was 5-fold higher than phosphate in normal muscle glycogen, which is in agreement with 
published results (Fig. 2D) (Tagliabracci et al., 2008). Iodine spectral scans of the purified LBs 
were compared to those of commercial glycogen and amylopectin, the major component of plant 
starch to which LBs are most similar. While glycogen has a peak maximum at ~440 nm when 
stained with Lugol's iodine, amylopectin has a right-shifted spectrum and a peak maximum at 
560 nm due to its reduced branching (Fig. 2E) (Krisman, 1962). The spectra of the purified LBs 
were also shifted toward longer wavelengths, with peak maxima at 510-520 nm (Fig. 2E). These 
data indicate that the purified LBs are less branched than glycogen, consistent with previous 
reports on Epm2a-/- and Epm2b-/- mice (Tagliabracci et al., 2008; Valles-Ortega et al., 2011).  
 Final LB preparations were also stained with Lugol's iodine and examined by light 
microscopy. Minimal tissue debris was observed and the LBs tended to clump (Fig. 2, F to H). 
LBs from different tissues also had noticeably distinct morphologies. Brain LBs were generally 
spherical, sub-spherical or irregularly shaped (Fig. 2F), and a range of sizes were observed: the 
maximum diameter of a single LB ranged from 1-10 μm, most being 2-4 μm (Fig. S3A). These 
preparations also had a significant amount of granular material that stained less intensely with 
iodine; small amounts of this material were visible throughout the slide but appeared to form a 
large aggregate in some fields of view (Fig. S3D). Similar PAS-positive granular material has 
been reported in fixed tissue sections from patient brain biopsies or LD mice, which are referred 
to as dust-like particles, or simply "dust" (Edgar, 1963; Machado-Salas et al., 2012; Van Heycop 
Ten Ham, 1975; Van Hoof and Hageman-Bal, 1967).  
 Heart LBs were more often ellipsoid or ovoid in shape, frequently with pointed ends, 
although some were sub-spherical like the brain LBs (Fig. 2G). Heart LBs also ranged in 
diameter/length from 1-10 μm, most of them being 2-4 μm (Fig. S3B). Dust-like particles were 
also observed among the heart LBs, although no masses of granular material were observed as 
with the brain LBs (Fig. S3E). LBs have been reported in LD patient cardiac tissue: in fixed and 
stained tissue sections, they are irregularly shaped or elongated with pointed ends (Edgar, 1963; 
Van Heycop ten Ham and Jager, 1963; Yokota et al., 1987; Yokota et al., 1988). Although these 
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reports do not discuss dust-like particles in the heart, they appear to be present in the 
micrographs, particularly in the studies that involve immunostaining with an LB-specific 
antibody (Yokota et al., 1987; Yokota et al., 1988). PAS-stained cardiac sections from malin KO 
mice show LBs of similar shape and size and diastase-resistant granular material (Criado et al., 
2012; DePaoli-Roach et al., 2010). LBs from skeletal muscle were the smallest and most 
homogenous in size and shape: the vast majority were ellipsoid and 1-3 μm long (Fig. 2H and 
S3C). There appeared to be virtually no dust in these preparations. In LD patients, LBs have 
been reported to similarly range in diameter from 0.2-2 μm in skeletal muscle (Van Heycop Ten 
Ham, 1975).  
 We also utilized SEM to visualize the purified LBs. We found that washing LBs in ethanol 
and allowing them to dry in a vacuum concentrator, the method used for visualization of starch 
granules, caused the LBs to aggregate and form very large clumps after being applied to carbon 
tape (Fig. S4). It was difficult to distinguish individual LBs within the clumps against the 
similarly textured carbon tape. As an alternative drying method, LBs were diluted in water, 
applied to a mounted silicon wafer and lyophilized prior to visualization. This method yielded 
less aggregated LBs and allowed for their morphological analysis. These micrographs showed 
that LBs from all three tissues had a similarly textured appearance (Fig. 3), in contrast to the 
smooth surface of starch (Fig. 1F). As observed via light microscopy, individual brain LBs up to 
10 μm in diameter were observed, which were spherical or irregularly shaped (Fig. 3A). Ovoid 
and ellipsoid LBs from heart and small ellipsoid LBs from skeletal muscle were also consistent 
with our light micrographic observations (Fig. 3B and C). Visualization of skeletal muscle LBs 
at very high magnification (30,000×) revealed the fine texture of the LBs (Fig. 3D). 
 
Degradation of LBs by VAL-0417 
As described above, native LBs purified from different tissues possess unique morphology. To 
determine if VAL-0417 could degrade the different types of LBs, we incubated 50 μg of Epm2a-
/- LBs from brain, heart and skeletal muscle with VAL-0417. We observed a consistent dose-
response effect: 1 μg VAL-0417 released 6-9 μg of glucan (i.e. an oligosaccharide composed of 
several glucose moieties) into the soluble fraction, indicating 12-18% of the LBs had been 
degraded (Fig. 4A). Increasing the dose to 10 μg of VAL-0417 released over twice as much, 15-
19 μg of glucan, corresponding to 30-38% of the total substrate. A small amount of soluble 
glucan (5 μg or less) was observed in the samples lacking enzyme, so we visualized the soluble 
fractions from each treatment by light microscopy. We observed some LB fragments in the 
soluble fraction that did not sediment with centrifugation for LBs with and without VAL-0417 
(Fig. S5). We consistently observed that mechanical agitation caused some LBs to fragment. 
However, agitation was required to keep the LBs in suspension.  
 We also purified LBs from skeletal muscle of 12-month-old Epm2b-/- mice and found they 
were indistinguishable from Epm2a-/- skeletal muscle LBs in appearance, size and iodine spectra 
(Fig. S6). We observed a comparable dose-response effect of VAL-0417 on Epm2b-/- LBs: 1 μg 
and 10 μg VAL-0417 released 16% and 32% of the total, respectively (Fig. 4A). In a similar 
experiment, we incubated LBs with 10 μg VAL-0417 overnight and then visualized the product 
by staining the insoluble fraction with Lugol's iodine. Untreated LBs had no change in 
appearance and appeared largely intact after the overnight agitation, but VAL-0417 treatment led 
to fewer iodine-positive LBs and the appearance of a filamentous degradation product (Fig. 4B).   
 Previous work has shown that various proteins are associated with LBs in vivo (Criado et al., 
2012; Machado-Salas et al., 2012). Our purification protocol removes these proteins, so it is 
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possible that an intact protein coat could inhibit LB degradation by VAL-0417. To test this 
possibility, we measured LB load in crude muscle homogenates after incubation with VAL-0417 
using iodine absorbance. While virtually no absorbance was detected at 550nm in the WT 
samples with or without VAL-0417 treatment, treatment of the Epm2a-/- samples with VAL-
0417 reduced iodine absorbance by >50%, indicating substantial LB degradation (Fig. 4C).  
 Since VAL-0417 is a potential therapeutic, it is important to define the soluble product(s) it 
releases from LBs. Pancreatic α-amylase is reported to release glucose, maltose, maltotriose and 
other short oligosaccharides (Robyt and French, 1967). Amylolytic products can be separated 
and quantified via high-performance anion-exchange chromatography coupled with pulsed 
amperometric detection (HPAEC-PAD). We digested LBs from Epm2a-/- skeletal muscle with 
VAL-0417 for a total of 168 hours with additional enzyme added every 24 hours. At 24-, 48- and 
72- hour time points, the soluble fractions of LB digestions were removed for HPAEC-PAD 
analysis. At all 4 time points, maltose and glucose were the major degradation products, 
followed by small amounts of oligosaccharides with 3, 4, 5 and 6 degrees of polymerization (DP-
3, 4, etc., where each DP corresponds to one glucose unit) (Fig. 4D and Fig. S7). Quantitation of 
the glucose and maltose peaks showed that maltose levels remained constant throughout 
degradation and glucose levels increased steadily over the 168-hour experiment (Fig. 4E). 
Cumulatively, these data demonstrate that VAL-0417 robustly digests brain, heart and muscle 
LBs in vitro. It is not inhibited by endogenous proteins in muscle homogenates, and its 
degradation products are primarily glucose and maltose, with a few short oligosaccharides. 
 
VAL-0417 uptake and polysaccharide degradation in situ  
To degrade LBs in vivo, VAL-0417 must penetrate and remain active inside cells. Cell 
penetration of the parent 3E10 mAb and its fragments require functional expression of the 
membrane equilibrative nucleoside transporter 2 (ENT2), which is involved in a nucleoside 
salvage pathway and is ubiquitously expressed in rodents and humans (Crawford et al., 1998; 
Hansen et al., 2007; Lu et al., 2004). VAL-0417 uptake and activity were assessed in two cell 
lines: fibroblast-derived Rat1 cells accumulating normal glycogen and HEK293 cells engineered 
to accumulate polyglucosan (HEK293-PTG/PP1Cα) (Fig. S8; see STAR Methods). After a 20-
hour treatment with increasing doses of VAL-0417, cells were washed, lysed, and probed for 
ENT2 and VAL-0417. ENT2 protein levels were stable in both lines, though Rat1 cells have 
slightly higher levels, and were unchanged with increasing concentrations of VAL-0417 (Fig. 
5A). Western blot analysis of VAL-0417 using an antibody for AMY2A revealed a dose-
dependent increase in protein levels (Fig. 5A). Total polysaccharide levels per well (glycogen in 
Rat1 cells and polyglucosan in HEK293-PTG/PP1Cα cells) were also measured. Both Rat1 and 
HEK293-PTG/PP1Cα lines displayed a dose-dependent decrease in total polysaccharide after 
treatment with VAL-0417 (Fig. 5B), with reductions of 30% and 26% of the untreated control, 
respectively. Thus, VAL-0417 is both taken up by cells and degrades glycogen and polyglucosan 
in situ. 
 
In vivo uptake of VAL-0417 and LB reduction in Epm2a-/- mice 
We have shown that VAL-0417 degrades LBs in vitro, penetrates cultured cells, and degrades 
glycogen and polyglucosan in situ. We next tested VAL-0417 uptake in an in vivo setting and 
biodistribution after peripheral injections. We performed intramuscular (IM) injections of VAL-
0417 to determine if it can be detected in the injected muscle and other tissues and if it is quickly 
degraded and/or cleared. We injected 0.6 mg VAL-0417 into the left gastrocnemius muscles of 
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WT C57BL/6 mice, then 2 and 24 hours post-injection, euthanized the mice and collected right 
and left gastrocnemii, right and left quadriceps, heart, liver, and brain. The same tissues were 
also collected 2 hours post-injection from control mice treated with phosphate-buffered saline 
(PBS). We designed a sandwich enzyme-linked immunosorbent assay (ELISA) to specifically 
detect VAL-0417 in tissue homogenates with very low background. At the 2-hour VAL-0417 
post-injection time point, 3200 ng of VAL-0417 per mg protein (15% of the injected amount) 
was detected in the injected (left) gastrocnemius (Fig. 6A). After 24 hours, VAL-0417 levels 
dropped by 20-fold (to 151 ng per mg protein), 0.7% of the initial injected amount. At 2 hours, 
low levels of VAL-0417 (2-9 ng per mg protein, 0.02-0.1% of the injected amount) were 
detected in the other muscles, heart, liver, and brain, indicating some VAL-0417 had entered 
circulation. After 24 hours, VAL-0417 levels nearly returned to baseline in muscles, liver, and 
brain, but remained constant in the heart. Since blood circulates the entire body of a mouse 
within minutes, the very high levels of VAL-0417 in the injected muscle 2 and 24 hours post-
injection strongly suggest that VAL-0417 is taken up by cells rather than immediately cleared. 
The low levels of VAL-0417 in non-injected tissues indicate VAL-0417 entered the circulation. 
In mice, ENT2 expression levels are high in brain, muscle and heart, and low in liver (Lu et al., 
2004). It is possible that these tissues took up a small amount of VAL-0417 from the circulation 
that was mostly cleared by 24 hours. ENT2 levels were probably not limiting since VAL-0417 
levels were similar regardless of tissue differences in ENT2 expression. It is notable that VAL-
0417 levels remained constant in heart even after 24 hours.  
 We next tested whether IM injections of VAL-0417 reduced polysaccharide levels in vivo in 
Epm2a-/- mice. To determine polysaccharide levels in individual muscles, we utilized the 
Pflüger method rather than our native LB protocol because the Pflüger method recovers ~100% 
of the polysaccharides, enables more accurate and sensitive measurements from small amounts 
of tissue, and yields both normal glycogen and LBs. 10-month-old WT and Epm2a-/- mice were 
injected in the right gastrocnemius with either 0.6 mg VAL-0417 or PBS. Three injections were 
performed over the course of one week, on days 1, 4, and 7. On day 8 the mice were euthanized, 
and the injected muscles were collected for total polysaccharide quantification. Polysaccharide 
levels in the WT mice were similar regardless of treatment, and consistent with reported skeletal 
muscle glycogen levels for C57BL/6 mice (Tagliabracci et al., 2008). In Epm2a-/- animals, 
VAL-0417 treatment reduced polysaccharide levels by 53% relative to the PBS-treated controls 
(Fig. 6B). These data indicate that in vivo, VAL-0417 does not decrease normal glycogen levels, 
but degrades LBs in Epm2a-/- mice.  
 Intravenous (IV) injections are sometimes preferable to IM injections to achieve rapid and 
extensive bioavailability of the drug to various tissues, but the preferred route depends on the 
drug (Jin et al., 2015). We tested whether a high dose of VAL-0417 administered intravenously 
could reduce LBs in the heart. Like skeletal muscle and brain, heart tissue has a very high LB 
load, and cardiac abnormalities have been reported in both LD mice and in patients (de Graaf et 
al., 1989; Oksel et al., 1999; Villalba-Orero et al., 2017). Furthermore, our biodistribution 
experiment indicated there was less turnover of VAL-0417 in the heart compared to other tissues 
(Fig. 6A). 8-month-old WT and Epm2a-/- animals were injected via the tail vein with either PBS 
or VAL-0417 over the course of two weeks, on days 1, 5, 8 and 13. The mice were euthanized on 
day 14, and hearts were removed and flushed with PBS. A small section of tissue was excised for 
fixation and periodic acid-Schiff (PAS) staining, and the remaining tissue was flash frozen and 
analyzed for polysaccharide content via the Pflüger method. The glycogen content of the heart in 
WT animals is very low in comparison to skeletal muscle (Pederson et al., 2004). Accordingly, 
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we found that polysaccharide levels in WT animals were very low levels irrespective of 
treatment (Fig. 6C). In contrast, polysaccharide levels in the PBS-treated Epm2a-/- mice were 
very high in comparison to the WT animals and were reduced by 67% after the two-week 
treatment regimen with VAL-0417 (Fig. 6C).  
 Results from the fixed, PAS-stained heart sections were consistent with polysaccharide 
quantification. PAS-positive deposits, i.e. LBs, were not observed in WT tissue irrespective of 
treatment and were abundant in tissue of PBS-treated Epm2a-/- mice (Fig. 6D and 6E). 
Conversely, Epm2a-/- mice treated with VAL-0417 showed a marked reduction in LBs (Fig. 6E). 
These data collectively indicate that after IM or IV injection, VAL-0417 penetrates cells, 
remains active, and degrades LBs in vivo.  
 Cerebral LB accumulation drives epilepsy and neurodegeneration in LD (Duran et al., 2014). 
Most drugs, particularly antibody-based drugs, do not cross the blood-brain barrier (Kumar et al., 
2018). Any therapy targeting cerebral LBs must be delivered into the CNS. There are multiple 
routes of drug administration to the CNS that bypass the blood-brain barrier. The intrathecal (IT) 
route involves injection of the drug directly into the spinal cord or the subarachnoid space. Drugs 
can also be injected directly into the ventricles of the brain via intracerebroventricular (ICV) 
injection. Both IT and ICV are considered safe and well-tolerated drug delivery routes in both 
pediatric and adult populations, but the procedures have different risks and benefits (Cohen-
Pfeffer et al., 2017; Kumar et al., 2018; Vuillemenot et al., 2016). 
 We first tested IT versus ICV administration of either PBS or VAL-0417 in WT mice over a 
period of 3 days. The IT catheter was surgically implanted intrathecally at the lumbar region. 
The ICV cannula was implanted in the cerebral lateral ventricle. The IT catheter and ICV 
cannula were each attached to an osmotic pump that delivered a continuous infusion of VAL-
0417 (0.08 mg/day) or PBS for 3 days. Mice were sacrificed on the fourth day and brains were 
removed and sectioned as shown (Fig. 7A). Homogenates from each section were analyzed via a 
VAL-0417 ELISA assay (Fig. S9A) and amylase assays were used to quantify VAL-0417 
activity (Fig. S9B). Negligible ELISA signal was detected in tissue treated with PBS either by IT 
or ICV, and amylase activity in the tissue was very low. In tissues treated with VAL-0417, VAL-
0417 levels were markedly higher with ICV administration compared to IT. In most slices, 
amylase activity was also markedly higher with ICV treatment of VAL-0417. After ICV 
administration, VAL-0417 levels and activity were nearly equal in all slices, indicating this route 
facilitates homogenous distribution of the drug throughout the brain. In contrast, IT 
administration only resulted in high VAL-0417 levels in the most caudal sections, which are 
nearest the brain stem. Since LBs are abundant throughout the cortex and cerebellum, a thorough 
distribution is necessary and thus ICV administration is preferable to IT. Furthermore, these data 
are indicative of cellular uptake of VAL-0417 in the brain, since the drug was not cleared in the 
period after infusion (day 3) and before euthanasia (day 4). These data also demonstrate that the 
drug remains active after uptake.  
 To target cerebral LBs, we administered VAL-0417 directly into the cerebral lateral ventricle 
of 5-month-old Epm2a-/- mice. A continuous infusion of VAL-0417 (0.08 mg/day) or PBS was 
administered for 28 days via the ICV cannula and pump. Mice were then euthanized, and brains 
were removed and sectioned as shown (Fig. 7A). Polysaccharides were isolated from each 
section, quantified, and normalized to protein levels. Polysaccharide levels relative to protein 
content were lowest in the rostral section and highest in the caudal section (Fig. 7B). This is the 
first- time polysaccharide distribution across different brain regions has been quantitated in 
Epm2a-/- mice, and is consistent with the high levels of LBs observed in histological sections 
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from brainstem and cerebellum (Criado et al., 2012; Rubio-Villena et al., 2018; Valles-Ortega et 
al., 2011). Treatment with VAL-0417 reduced the polysaccharide load in all sections, with 
statistical significance in the two most caudal sections that contain the highest glucan load (Fig. 
7B).  
 To define initial pre-clinical parameters regarding optimal treatment length, we performed a 
second ICV experiment to determine whether a shorter treatment regimen still reduced the 
amount of polysaccharide in the brain. 7-month old Epm2a-/- mice received a continuous 
infusion of VAL-0417 at an equivalent rate (0.08mg/day) or PBS for 7 days. On the 8th day, the 
mice were euthanized, and the brains were hemisected along the medial longitudinal fissure. The 
left hemisphere was frozen and pulverized for biochemical analyses, and the right hemisphere 
was fixed and sectioned for PAS staining. The brains of age-matched untreated cohorts of WT 
and Epm2a-/- animals were similarly analyzed as surgical controls. Polysaccharide levels relative 
to tissue weight in untreated and PBS-treated animals were consistent with what has been 
previously reported for Epm2a-/- animals of this age, i.e. 2-3 times higher than WT levels (<2 
μmol glucose/g tissue) (Nitschke et al., 2017; Tagliabracci et al., 2008). Treatment with VAL-
0417 reduced brain polysaccharide in the Epm2a-/- mice by 69% compared to untreated and 
PBS-treated Epm2a-/-  mice (Fig. 7C). The amount of VAL-0417 in the treated brains was 249 
ng per mg protein (Fig. 7D). This value is slightly higher than the VAL-0417 levels in the 
injected gastrocnemius 24 hours after IM injections in WT mice (Fig. 6A). Fixed and PAS-
stained tissue slices showed an abundance of LBs in the PBS-treated Epm2a-/- brains similar to 
age-matched untreated Epm2a-/- controls with no observable LBs in age-matched WT animals 
(Fig. 7E and Fig. S10).  In the untreated and PBS-treated Epma2-/- animals, LBs were least 
abundant in the frontal cortex, more abundant in the thalamus, and most abundant in the 
cerebellum and brainstem (Fig. S10). This regional distribution is very consistent with the slice-
specific quantification we performed via the Pflüger method (Fig. 7B). Strikingly, the VAL-0417 
treated Epm2a-/- brains are virtually devoid of LBs in all regions (Fig. 7E, S10). . 
 
Metabolomic profiles as a biomarker for VAL-0417 treatment  
It is critical to establish that the reduction of LBs in the brain produces a physiological 
amelioration of LD pathology. However, like many mouse models of human diseases, LD 
models do not completely recapitulate the human phenotype (Perlman, 2016). In contrast to 
patients, LD mice do not have a reduced lifespan, neurophysiological impairments are difficult to 
detect in young mice, and in older mice, they are often significant only by a small margin 
(Ganesh et al., 2002; Garcia-Cabrero et al., 2012; Garcia-Cabrero et al., 2014; Sanchez-Elexpuru 
et al., 2017). Furthermore, although older mice develop myoloclonic jerks, they do not have 
spontaneous grand mal seizures (Ganesh et al., 2002; Turnbull et al., 2011; Valles-Ortega et al., 
2011). Seizure susceptibility must be detected in older mice using kindling agents such as 
pentylenetetrazol or kainate (Duran et al., 2014; Garcia-Cabrero et al., 2014; Valles-Ortega et al., 
2011). The discrepancy between human and mouse phenotypes is a particularly common issue 
that arises when studying neurological diseases. The extreme differences between the size, 
lifespan, and complexity of the two species are just a few of the potential causes of this problem 
(Dawson et al., 2018).  
 Conversely, metabolic pathways are more highly conserved between rodents and humans, 
especially disease models. The metabolic signatures of Alzheimer’s disease mouse models 
parallel those of patients and are therefore readily translatable (Trushina and Mielke, 2014). 
Metabolomic similarities between humans and mice have also been observed in Huntington’s 
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disease, type 2 diabetes, nonalcoholic fatty liver disease, and colorectal tumors (Barr et al., 2010; 
Manna et al., 2014; Salek et al., 2007; Underwood et al., 2006). It is likely that the metabolic 
changes that underlie a disease are similar in the two species, although they may have species-
specific physiological manifestations.  
 Glycogen is formed from UDP-glucose, and its catabolism leads to the release of glucose-1-
phosphate, which is rapidly converted to glucose-6-phosphate (Brown and Ransom, 2007). 
Glucose-6-phosphate is a central molecule in cellular metabolism, supplying carbon for 
glycolysis, the pentose phosphate pathway, and amino acid synthesis. Therefore, altered brain 
glycogen metabolism is expected to produce measurable shifts in the cerebral metabolome. We 
sought to measure these changes in the cerebral metabolome to define the physiological outcome 
of VAL-0417 treatment. We utilized gas chromatography-mass spectrometry (GCMS) to assess 
central carbon metabolites of glycolysis and the TCA cycle, as well as amino acids, nucleotides, 
and mono-, di- and trisaccharides (Fiehn, 2016; Fiehn et al., 2000; Kind et al., 2009). Polar 
metabolites were extracted from the pulverized brain tissue of the same mice that were treated 
with PBS or VAL-0417 via ICV for 8 days. Age-matched untreated WT and Epm2a-/- animals 
were used as controls. We identified over 100 metabolites from all four treatment groups to 
utilize in a multivariate analysis, which included both principle component analysis (PCA) and 
heat map clustering. The metabolites analyzed and relative abundance of each are listed in Table 
S1. The 2-dimensional PCA plot using all available metabolomic data revealed three discrete 
clusters (Fig. 7F). Metabolites of untreated WT and Epm2a-/- groups segregated into two 
discrete groups, while metabolites of the PBS-treated Emp2a-/- mice comprised a third group. 
The metabolic differences between the untreated and PBS-treated animals are likely due to the 
physiological effects of surgery and ventricular infusion. Strikingly, metabolites of the VAL-
0417 treated Epm2a-/- mice clustered tightly within the WT group, indicating that after LB 
degradation by VAL-0417 the cerebral metabolism returned to normal. We further corroborated 
this result with clustering heatmap analysis (Fig. S11). While the metabolic profiles of the 
untreated Epm2a-/- animals were distinct, metabolites of the VAL-0417 treated Epm2a-/- 
animals were interspersed with the WT animals.  
 We previously demonstrated that VAL-0417 degrades LBs in vitro by releasing glucose, 
maltose and short oligosaccharides (Fig. 4D and 4E). To determine whether oligosaccharides 
were accumulated in the brain tissue, the relative spectral abundance of mono-, di- and tri-
saccharides was determined. There was a significant increase in each oligosaccharide in the brain 
tissue from the VAL-0417 treated Epm2a-/- animals compared to the other groups (Fig. 7G). 
These results coupled with the overlapping metabolic profile of the VAL-0417 treated animals 
with the untreated WT animals demonstrate the effectiveness of VAL-0417 and metabolic 
profiling as a means to assess treatment efficacy.   
 
Discussion  
LD is caused by mutations in one of two genes both encoding enzymes that impact glycogen 
architecture. Efforts from multiple labs have shown that LBs are the pathogenic epicenter of LD, 
and LB removal has become a therapeutic approach for the treatment of LD (Brewer and Gentry, 
2018; Brewer et al., 2019). In this study, we combine insights from the fields of antibody-based 
therapeutics, GSDs, carbohydrate metabolism, and LD to design an AEF that degrades LBs in 
vitro, penetrates cells and reduces polysaccharide levels in situ, and decreases polysaccharide 
load in vivo via both IM and ICV injection. This is the first time a significant LB reduction has 
been achieved in adult LD mice by the use of a drug and the first report of overall brain 
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metabolism in LD mice. Importantly, we define the use of metabolomics for monitoring drug 
efficacy in LD mouse models. 
 Antibody-based drugs have made a major impact on the treatment of cancer, autoimmune 
and inflammatory diseases with worldwide revenues of ~$89 billion in 2016 (Carter and Lazar, 
2018). Antibody-based drugs are typically whole IgGs designed to bind and block receptors, 
deplete target cells, downregulate a receptor or initiate signaling. Bispecific antibodies, antibody 
fragments and antibody-drug conjugates (ADCs) are also being developed across multiple 
diseases, further expanding the diversity of therapeutics utilizing antibody targeting  (Baeuerle 
and Reinhardt, 2009; Beck et al., 2017; Carter and Lazar, 2018; Moolten and Cooperband, 1970). 
In this report, we report a novel class of antibody-based drugs with a similar construction to 
ADCs: antibody-enzyme fusions (AEFs). Rather than delivering a cytotoxin, AEFs deliver an 
enzyme to a specific target. The antibody or antibody fragment is essential both for targeting and 
cellular penetration. AEFs have recently been reported for the treatment of multiple congenital 
disorders, including a muscle wasting disorder known as X-linked myotubular myopathy and the 
GSD Pompe disease. For X-linked myotubular myopathy, the deficient lipid phosphatase 
myotubularin fused to an Fv fragment was delivered by intramuscular injection and improved 
muscle function in a mouse model of myotubular myopathy (Lawlor et al., 2013). For Pompe 
disease, a Fab fragment fused to GAA delivered intravenously reduced glycogen load and 
alleviated pathology in GAA-deficient mice (Yi et al., 2017). These two studies illustrate that 
enzyme replacement therapy, which can be problematic for cytosolic enzymes, can be enhanced 
by fusion of the replacement enzyme with a cell-penetrating antibody fragment. We now 
demonstrate that VAL-0417, an AEF comprised of a Fab fragment fused to pancreatic α-
amylase, degrades LBs and reduces polysaccharide loads in vivo. Unlike the two studies above, 
VAL-0417 does not replace a missing enzyme, but rather delivers a natural human enzyme to a 
new target. Since LBs are structurally similar to plant starch, and α-amylase naturally degrades 
dietary starch in the human digestive tract, α-amylase is a logical choice for the VAL-0417 
payload. 
 It is important to distinguish normal glycogen from polyglucosan. Polyglucosan bodies 
(PGBs) have been defined as "small, non-membrane-bound cytoplasmic structures composed 
largely of unusual glucose polymers" (Raben et al., 2001). They are typically a pathological 
feature of GSDs, although PGBs known as corpora amylacea are a hallmark of normal aging and 
neurodegenerative disorders (Augé et al., 2018; Cavanagh, 1999). PGBs are not found in all 
GSDs, and not all PGBs are identical with respect to physiochemical structure. The polyglucosan 
found in Cori's disease is characterized by short outer chains, while the polyglucosan of LD, 
Anderson disease, Adult Polyglucosan Body Disease, and Tarui disease contain very long chains 
(Illingworth and Cori, 1952; Raben et al., 2001). The Pflüger method, originally designed to 
purify normal glycogen, also precipitates polyglucosan. In this report, we refer to Pflüger-
isolated material as polysaccharide, since it contains both glycogen and polyglucosan. 
Furthermore, the Pflüger method includes an alkaline boiling step that solubilizes polyglucosan 
and destroys LB superstructure. LBs (and PGBs) may be considered a higher-order structure of 
polyglucosan. The LB purification protocol we designed does not include the alkaline boil. 
Rather, it separates native LBs from normal, soluble glycogen.  
 LBs from the different tissues displayed varied morphologies. Brain LBs were the most 
irregular in size and shape, included dust-like particles, and reached the largest size. LBs from 
brain exhibited the greatest variation in size, which is consistent with clinical observations: LBs 
from patient brain micrographs are 3-40 μm and LB dust-like granules are even smaller 
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(Minassian, 2001; Van Heycop Ten Ham, 1975). A recent microscopic study of Epm2b-/- mice 
showed that astrocytic LBs are on average smaller than neuronal LBs, more irregularly shaped, 
and clustered, while neuronal LBs are larger, more spherical, and isolated (Augé et al., 2018). 
LBs in the heart were also surprisingly large and included some dust-like particles. LBs from 
skeletal muscle appeared well organized: they were very small and homogenous in shape, and no 
dust-like particles were present. It is not clear why such variation in LB size and shape exists in 
the brain and heart, in contrast to the homogeneity found in skeletal muscle. One possibility is 
that LB size is limited by the dimensions of the cell or subcellular region it occupies. For 
example, in patients, dogs, and mice, LBs can be found in the cell bodies of Purkinje neurons, 
which can be up to 40 μm in diameter (Jian et al., 1990; Machado-Salas et al., 2012; Van Heycop 
Ten Ham, 1975). In astrocytes, LBs are typically found in processes, which can be very long but 
are only a few microns wide (Augé et al., 2018; Rubio-Villena et al., 2018). However, cell size 
constraints do not explain the difference between heart and skeletal muscle LBs, since cardiac 
and skeletal myocytes are similar in size. It is well known that glycogen metabolism is 
remarkably different in astrocytes, neurons, cardiomyocytes and skeletal myocytes. Skeletal 
myocytes may sequester LBs more efficiently than cardiomyocytes, consolidating them into 
smaller, discrete units. In brain and heart, the dust-like particles may represent a pre-aggregated 
form of polyglucosan, while the larger particles may represent polyglucosan aggregates that have 
been sequestered and compacted by the cell. Active cellular sequestration of polyglucosan has 
been proposed to explain the large, dense, and spherical LBs observed in some neurons 
(Machado-Salas et al., 2012).  
 Although LBs from all three tissues had iodine spectral peak maxima at similar wavelengths, 
indicative of similar degrees of branching, the higher amplitude of the spectra of brain and heart 
LBs suggests that they may contain longer chains compared to LBs from skeletal muscle 
(Krisman, 1962; Swanson, 1948). Indeed, Nitschke et al. showed using HPAEC-PAD that in 
Epm2a-/- and Epm2b-/- mice, brain glycogen had a more exacerbated shift in chain length 
distribution than muscle glycogen (Nitschke et al., 2017). Although the brain is most severely 
affected in LD and a neurological phenotype predominates, heart failure and arrhythmia have 
been reported in LD patients, and Epm2a-/- and Epm2b-/- mice have metabolic cardiomyopathy 
(de Graaf et al., 1989; Oksel et al., 1999; Villalba-Orero et al., 2017). Glycogen metabolism is 
variable with tissue type: glycogen synthase and glycogen phosphorylase have tissue-specific 
isoforms that are disparately regulated by cellular signals (Roach, 2002); the ultrastructure of 
glycogen is different under different metabolic conditions and in different organs (Ryu et al., 
2009; Sullivan et al., 2014); subcellular glycogen pools are variable (Graham et al., 2010); and 
both phosphate levels and average chain length differ with species and tissue type (Illingworth et 
al., 1952; Lomako et al., 1993). Due to these differences, the LBs may be more pathological in 
brain and heart than in skeletal muscle. Conversely, different cell types may be more sensitive to 
the presence of the LBs, and/or the metabolic perturbations induced by the LBs may have 
distinct consequences in different organs. Tissue-specific differences are important to consider 
throughout the clinical development of VAL-0417. ICV administration of VAL-0417 may 
attenuate neurological symptoms, but cardiac, liver and/or muscular pathology may require 
treatment by intravenous or intramuscular injection of VAL-0417.  
 We found that VAL-0417 primarily releases maltose and glucose from LBs, and glucose 
levels gradually increased over time, as expected for an α-amylase. Cytosolic free glucose would 
likely be phosphorylated to produce glucose-6-phosphate, entering central carbon metabolism. 
Although maltose is not considered a typical participant in intracellular energy utilization, 
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studies have shown that maltose can be transported into and out of cells and metabolized in cell 
culture and humans after intravenous infusion (Leong et al., 2017; Young and Weser, 1971). The 
small oligosaccharides (DP-3, DP-4, etc.) would likely remain cytosolic and inert until they are 
further metabolized to glucose and maltose. Our metabolomics approach revealed a significant 
increase in mono-, di- and trisaaccharides in the VAL-0417 treated brains. These in vivo data 
strongly support our in vitro oligosaccharide profiling of VAL-0417 degradation products. 
Strikingly, the metabolomic profile of Epm2a-/- mice treated with VAL-0417 is 
indistinguishable from the WT mouse metabolic profile.  These data strongly suggest that the 
oligosaccharide products are not detrimental and may be metabolically inert.  
 Importantly, IM and IV injections of VAL-0417 in Epm2a-/- mice reduced the 
polysaccharide load (i.e. LBs and glycogen) to WT levels but did not decrease glycogen levels in 
WT skeletal muscle or heart, respectively. Glycogen levels in WT heart tissue is already very 
low, and the levels remained negligible after IV treatment with VAL-0417. In contrast, we 
observed that VAL-0417 reduced polysaccharide levels in cell culture. It should be noted that the 
cell culture studies were performed in high glucose media, known to promote glycogen 
accumulation and the cells are engineered to increase glycogen levels. Thus, it is possible that a 
reduction in polysaccharides with VAL-0417 treatment is only detected when polysaccharide 
levels accumulate above a baseline level, as glycogen accumulates in cultured cells or LB in LD 
tissues. When glycogen levels drop below a certain threshold due to degradation by VAL-0417, 
the cellular machinery may respond to restore those levels. Glycogen is likely to be maintained at 
a certain baseline level in vivo in muscle, and this may explain why no change was observed in 
WT muscle treated with VAL-0417. The observation that VAL-0417 reduced polysaccharide 
levels in Epm2a-/- muscle, heart and brain indicates LBs are degraded in vivo.  
Although both IT and ICV injections are performed in the clinic, delivery to the CNS 
remains a significant challenge (Calias et al., 2014; Wolak and Thorne, 2013). Drug distribution 
is highly dependent on fluid movement in the CNS, which is a relatively nascent field of research 
(Abbott et al., 2018; Kumar et al., 2018; Plog and Nedergaard, 2018). While the field has defined 
fluid movement, detailed biodistribution of actual drugs via ICV and IT delivery is ongoing 
(Kumar et al., 2018). In this study, we demonstrate that a 150 kDa AEF is modestly distributed 
throughout the brain after IT administration and maximally distributed by after ICV 
administration (Fig. S9). Similarly, ICV administration of anti-amyloid antibodies for the 
treatment of Alzheimer’s disease resulted in widespread distribution throughout the murine brain 
(Chauhan and Siegel, 2004). Our data support a recent study demonstrating that the 
bioavailability of antibodies to the brain after IT injection is size-dependent (Pizzo et al., 2018). 
Our results indicate that VAL-0417 can cross cellular barriers between the ventricles and brain 
parenchyma (e.g. ependyma, perivascular lining cells, and/or pia and glia limitans), they also 
highlight the differences in drug permeability and diffusion between the ICV and IT routes. 
 Importantly, we utilized a metabolomics approach to quantify the physiological effects of 
VAL-0417 treatment. Using principal component analysis, we found that the profile of polar 
brain metabolites from WT and Epm2a-/- mice cluster into discreet groups. Treatment of Epm2a-
/- mice with the VAL-0417 shifted the Epm2a-/- profile to mimic the WT cluster, reflecting a 
restoration of normal metabolism. These results illustrate a positive physiological response and 
amelioration of metabolic derangement in LD animals after VAL-0417 treatment. Studies in 
multiple disease contexts have shown that the metabolic changes in humans and mice are highly 
correlated (Barr et al., 2010; Manna et al., 2014; Salek et al., 2007; Trushina and Mielke, 2014; 
Underwood et al., 2006). Furthermore, metabolomics is now being employed to identify 
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biomarkers in human biofluids or tissues for monitoring disease progression and therapy efficacy 
(Johnson et al., 2016; Spratlin et al., 2009). A particularly relevant example is the use of the 
tetrasaccharide glucose (Glc4) as a biomarker for Pompe disease (Bobillo Lobato et al., 2016). 
Elevated levels of Glc4 have also been observed in patients with GSD Ia and III, and urinary 
excretion of the Glc4 in Pompe patients correlates with response to Myozyme treatment (An et 
al., 2005; Manwaring et al., 2012). The dramatic upregulation of oligosaccharides in VAL-0417 
treated mouse brain tissue suggests these molecules could be utilized as biomarkers for VAL-
0417 therapy in humans.  
 We have demonstrated that VAL-0417 is a putative precision therapy for LD, an intractable 
epilepsy. Currently, >30% of epilepsies, including LD, are resistant to available antiseizure drugs 
(ASDs) and are known as refractory epilepsies (Loscher and Schmidt, 2011). More than 35 
different iterations of ASDs have been discovered over the past 150 years with most of them 
acting primarily on ion channels or neurotransmitters. Due to this focus on one mode of action, 
the high proportion of refractory epilepsies has remained constant since the 1850s (Loscher and 
Schmidt, 2011; Scharfman, 2015). The underlying causes of these refractory epilepsies must be 
identified in order to develop more effective therapies. As the molecular basis of LD has been 
defined, we have now developed an AEF that targets its underlying cause. As molecular 
etiologies in other epilepsies become clear, precision therapies, possibly also utilizing the AEF 
platform, become feasible. LD is also a non-classical GSD. There are over 14 different types of 
GSDs characterized by glucan accumulations, and 1 in 20,000 people have some form of GSD 
though the individual types are considered rare (Adeva-Andany et al., 2016; Ozen, 2007). While 
the glycogen in some GSDs is of normal structure like in Pompe disease, other GSDs such as 
Cori disease and Andersen disease are characterized by polyglucosans, like LD (Adeva-Andany 
et al., 2016). Two AEF drugs (VAL-0417 and Fab-GAA) have now been shown to target 
cytosolic polyglucosan (the present study) and normal glycogen in both the cytosol and 
lysosome, respectively (Yi et al., 2017). These drugs could be repurposed and/or modified to 
target glycogen in other GSDs. Not only is VAL-0417 the first drug with the potential for 
providing a significant clinical benefit to LD patients, it is an example of a precision therapy and 
expands the repertoire of antibody-based drugs that can be used to treat human disease.  
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Limitations of Study 
This study employs LD mouse models and the use of metabolomics to determine the 
physiological benefit of LB degradation by VAL-0417. Metabolomics is an extremely powerful 
technique routinely used for biomarker discovery, and it is increasing utilized to provide insights 
into disease onset, progression and response to therapy (Johnson et al., 2016). Although the 
metabolic changes in humans and mice are often strongly correlated (Barr et al., 2010; Manna et 
al., 2014; Salek et al., 2007; Trushina and Mielke, 2014; Underwood et al., 2006), our analysis 
provides only a general overview of the physiological and metabolic state of the brain. It is not 
possible to determine the relative contributions of cellular populations (e.g. neurons and glia) or 
specific pathway aberrations (e.g. oxidative stress and proteostasis) to the metabolic profiles. 
Finally, like all mouse models of neurological diseases, LD mice do not perfectly phenocopy the 
human disease. Further pre-clinical studies will be conducted to validate the physiological 
benefit of VAL-0417 administration and LB degradation for the treatment of LD. 
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STAR�Methods  
 
CONTACT FOR REAGENT AND RESOURCE SHARING  
Researchers may obtain VAL-0417 with a material transfer agreement from Valerion 
Therapeutics. All reasonable requests for collaboration involving materials used in the research 
will be fulfilled provided that a written agreement is executed in advance between Valerion 
Therapeutics and the requester (and his or her affiliated institution). Further information and 
requests for reagents may be directed to, and will be fulfilled by the corresponding author 
Matthew S. Gentry (matthew.gentry@uky.edu). 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS  
 
Mice 
Epm2a-/- (DePaoli-Roach et al., 2012; Ganesh et al., 2002) and Epm2b-/- (DePaoli-Roach et al., 
2010) mice have been previously described. C56Bl/6 WT, Epm2a-/- and Epm2b-/- animals were 
maintained in a 12:12 hr light-dark cycle and were given ad libitum access to food and water. 
Both male and female mice were used since there are no sex differences associated with LD 
(Gentry et al., 2018). All procedures were approved by the UK Institutional Animal Care and 
Use Committee (IACUC) as specified by the 1985 revision of the Animal Welfare Act.  
 
METHOD DETAILS 
 
Expression and purification of VAL-0417  
VAL-0417 was designed and produced by Valerion Therapeutics (Concord, MA). The cDNA 
encoding the human IgG1 Fab-linker-AMY2A heavy chain and light chain were synthetically 
produced with codon optimization for mammalian cell expression and cloned into pTT5. 
HEK293 cells expressing a truncated variant of the Epstein Barr Virus nuclear antigen 1 
(HEK293-6E) increase the volumetric yield of monoclonal antibodies and fragments and were 
used for VAL-0417 expression (Jager et al., 2013).  2 1L cultures of HEK293-6E cells in 2L 
shake flasks were transfected with 1 mg of total plasmid DNA/L (1:1 ratio heavy chain:light 
chain) culture using PolyPlus linear Q-PEI at a 1:1.5 (w/v) DNA:PEI ratio. Culture parameters 
were monitored using a ViCell XR (Beckman Coulter) for density and viability. Culture was 
harvested 5 days post transfection via centrifugation for 5 minutes at 1000×g. The conditioned 
culture supernatant was clarified by centrifugation for 30 minutes at 9300×g.  
 Pre-packed CaptureSelect IgG-CH1 affinity columns (Fisher) were equilibrated in PBS (pH 
7.2). VAL-0417 from 2 L of exhausted supernatant was top-loaded onto affinity columns (2 x 1 
mL columns in tandem) at 4°C overnight. The column was washed with approximately 15 
column volumes (CV) of PBS, 15 CV of buffer B (1×PBS with 500 mM NaCl, pH 7.2) and 15 
CV of PBS. The resin-bound fusion protein was eluted with 10 CV of Buffer C (30 mM NaOAc, 
pH 3.5-3.6), collecting the protein in 1 mL fractions diluted in 1/10th volume Buffer D (3 M 
NaAcetate pH~9.0) to neutralize. To minimize the elution volume, elution was paused for 
several minutes between each fraction collected. Fractions were analyzed by A280 prior to 
pooling fractions and pools were analyzed by SDS-PAGE. VAL-0417 remained in the non-
bound pool from the first affinity chromatography pass. The above procedure was repeated to 
capture remaining fusion protein. The affinity pools were combined prior to dialysis. The 
combined CaptureSelect IgG-CH1 affinity pool (18 mL) was dialyzed against 3 x 1 L of dialysis 
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buffer (20 mM Histidine, 150 mM NaCl, pH 6.5) at 4°C. The dialyzed pool was concentrated to 
1 mg/mL using a VivaSpin 20 (10K MWCO, PES membrane) centrifugal device prior to final 
analysis and storage at -80°C. Purified Fab-AMY was analyzed by size exclusion 
chromatography (Agilent HP1100) showing a single peak before and after a freeze-thaw cycle, 
indicative of a single, stable species. Activity of the purified protein was quantified by an 
amylase activity colorimetric kit (BioVision) utilizing the amylase-specific E-G7-pNP substrate 
(Kruse-Jarres et al., 1989).   
 
Iodine-based measurements 
Lugol's iodine was prepared as a 20×stock (1.5 M KI and 100 mM I2). To detect LBs in 
preliminary purifications, 50 μL samples from purification fractions were boiled for 15 minutes 
on a 95°C heat block, clarified by centrifugation (16,000×g for 1 min), and 35 μL of the 
supernatant was added to 50 μL 1×Lugol's iodine and 15 μL water for 100 μL total (Fig. S2A). 
To analyze iodine absorbance of polysaccharide from LB purifications, Pflüger-isolated 
polyglucosan fractions were added to 50 μL 1×Lugol's iodine for 100 μL total and absorbance 
was measured at 550 nm. Absorbance was graphed alongside glucose-based concentrations to 
illustrate the fractionation of polyglucosan and glycogen into supernatant and pellet fractions, 
respectively (Fig. S2B). For spectral scans, 50 μg LBs, rabbit liver glycogen (Sigma), and potato 
amylopectin (Sigma) were solubilized by boiling for 30 min and added to 50 μL 1×Lugol's 
iodine for 100 μL total. Absorbance scans were performed at 400-800 nm in 10 nm steps. 
 
Purification of native LBs  
19-24 month old Epm2a-/- mice were euthanized by CO2 and decapitation, and brain, heart and 
hindlimb skeletal muscle were immediately harvested, flash frozen and stored at -80°C. 12 
month old Epm2b-/- mice were euthanized by cervical dislocation, and muscle tissues were 
similarly collected and stored. Tissues were pulverized over liquid N2 using a Freezer/Mill 
Cryogenic Grinder (SPEX SamplePrep). Powdered tissue was weighed and homogenized on ice 
in 4 vol. lysis buffer (100 mM Tris-HCl pH 8.0, 200 mM NaCl, 1mM CaCl2, 0.5% sodium azide) 
using a Dounce tissue grinder. For larger volumes, the grinding pestle was attached to a 
motorized drill. The homogenate was centrifuged for 10 min at 10,000×g at 4°C in a Ti-70 rotor 
and Optima XPN-90 ultracentrifuge (Beckman Coulter) and the supernatant was removed. The 
pellet was resuspended in an equivalent volume of lysis buffer, and 20% SDS was added for a 
final concentration of 0.2%, and 20 mg/ml Proteinase K was added for a final concentration of 
0.4 mg/ml. Proteolytic digestion was performed in a 37°C water bath overnight. The digested 
samples were then syringe-filtered through 140 μm and 60 μm nylon net filters installed in 
Swinnex filter holders (Millipore), centrifuged at 16,000×g for 5 min, and the supernatant was 
removed. The LBs were resuspended in 10% SDS and then washed 5 times in LB buffer (10 mM 
HEPES-KOH pH 8.0, 0.1% sodium azide) each time with centrifugation at 16,000×g for 5 min. 
Final LB pellets were gently and thoroughly dispersed in LB buffer with a pipet. Polysaccharide 
yield at various steps of the purification were determined using the Pflüger method (see below). 
2 μL of LB preparations were stained with 5 μL 20× Lugol's iodine, mounted on glass slides with 
a glass coverslip, and visualized at 100x using a Zeiss Axioimager Z1 equipped with an 
AxioCam 1Cc5 color camera. Purified LBs were stored at -20°C.  
 
Pflüger method for polysaccharide isolation  
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Glycogen and polyglucosan from Epm2a-/- and Epm2b-/- mice have been purified and 
characterized by multiple groups using the Pflüger method, but a chaotropic salt must be added 
to enhance the efficiency of polyglucosan precipitation (Tagliabracci et al., 2008). We wanted to 
clarify that under native conditions, and prior to the Pflüger treatment, LBs in Epm2a-/- and 
Epm2b-/- tissues are intact, micron-sized structures (Fig. 2 F to H, Fig. 3, and Fig. S5B). Pflüger 
treatment converts the LBs to much smaller polysaccharide molecules that are on the same 
nanometer scale as glycogen molecules, but they contain elevated phosphate and an altered chain 
length distribution (Nitschke et al., 2013; Tagliabracci et al., 2008). Thus, the term "LB" refers to 
the native, micron-sized polysaccharide-containing structures found in LD tissues, and 
"polyglucosan" refers to the abnormal polysaccharide comprising LBs, which is released with 
Pflüger treatment.  
 The Pflüger method is direct and very sensitive and was used to track polysaccharide yield 
throughout the native LB purifications or to detect polysaccharide content of mouse tissues for in 
vivo studies. Aliquots from native LB purifications or tissue homogenates were added to 10 vol. 
30% KOH, boiled for 2 hours, and allowed to cool. 2 vol. cold ethanol and 10 μL LiCl (1 M or 
20 mM) were added, and samples were precipitated overnight at -20°C. Precipitated samples 
were centrifuged for 10 min at 16,000×g at 4°C, the supernatant was removed, and the 
polysaccharide pellet was resuspended in water. Two additional precipitations with cold ethanol 
and LiCl were carried out, each for 1-2 hours at -20°C. The final pellet was washed in cold 
ethanol and resuspended with vortexing in 200 μL water. Polysaccharide was quantified by 
overnight hydrolysis with amyloglucosidase from Aspergillus niger (Sigma) and glucose 
determination was carried out using the D-glucose kit (Fisher). Fluorescence (ex340/em445) 
rather than absorbance of the NADPH product (stoichiometric to glucose) was measured for 
higher sensitivity.  
 
Separation of glycogen and LBs in LB purification  
After the initial centrifugation step in the LB purification, a fraction of the heart and muscle 
glycogen was consistently present in the supernatant (Fig. 2, B and C). In our preliminary 
purifications, we found that the homogenate and pellet fractions stained brown with Lugol's 
iodine after boiling, as did the final LBs and amylopectin, but the supernatants stained yellow 
like glycogen (Fig. S2A). We also stained the Pflüger-purified polysaccharide fractions from our 
large-scale preparations in Figure 2C with Lugol's iodine, measured absorbance at 550 nm, and 
compared the values to the polysaccharide concentrations determined by hydrolysis and glucose 
measurement (Fig. S2B). While the polysaccharide from the supernatant did not absorb at 550 
nm, polysaccharide from the pellet, filtrate and final fractions produced a high absorbance 
relative to concentration. Polysaccharide in the homogenate fraction was less absorbent relative 
to concentration. These data indicate that the polysaccharide in the heart and muscle tissue 
homogenates included both glycogen and polyglucosan (in the form of LBs), that were separated 
into supernatant and pellet fractions after low-speed centrifugation. No polysaccharide was 
detected in the supernatant fractions from brain (Fig. 2, B and C). This result is consistent with 
the observation that in normal mice, glycogen levels are lower in brain than in other tissues in 
part due to its rapid catabolism after euthanasia (Oe et al., 2016). 
 
Determination of LB phosphate content 
Muscle glycogen and LBs contain covalent phosphate linked to the C2, C3, and C6 hydroxyls of 
glucose moieties, and the relative ratios of these modifications are equivalent (DePaoli-Roach et 
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al., 2015; Nitschke et al., 2013; Tagliabracci et al., 2011). Boiling in mild HCl hydrolyzes 
glycosidic bonds and releases the acid-labile C2- and C3-linked phosphate leaving C6 
phosphoesters intact in the form of glucose-6-phosphate (Nitschke et al., 2013). Thus, inorganic 
phosphate after mild acid hydrolysis represents only C2- and C3-linked phosphate, i.e. two-thirds 
of total phosphate. To determine phosphate content, skeletal muscle LBs were boiled for 2 hours 
at 95°C in 1 M HCl. Reactions were neutralized with NaOH and inorganic phosphate in the 
sample was determined using the Pi ColorLock Gold Phosphate Detection System (Innova 
Biosciences). Glycogen purified from rabbit skeletal muscle as previously described was used as 
a positive control, and the levels of phosphate detected using our method are consistent with two-
thirds of published total phosphate levels (DePaoli-Roach et al., 2015).  
 
In vitro degradation assays 
Corn starch and LB degradation experiments were performed in degradation buffer (30 mM 
HEPES-KOH pH 7.5, 5 mM MgCl2, 5 mM CaCl2) and a total volume of 100 μL. Reactions were 
performed in triplicate using PCR strip tubes and moderate agitation on a vortex to keep 
substrates in suspension, and we found that this level of agitation did not affect enzyme activity. 
Degradation reactions were allowed to proceed overnight (13-18 hours) unless otherwise 
indicated, after which tubes were centrifuged to pellet undigested substrate. 50 μL of the 
supernatant (containing the soluble degradation product) was transferred to a new tube with 50 
μL 2 M HCl and boiled for 2 hours at 95°C in a C1000 thermocycler (Bio-Rad) to hydrolyze all 
glucans to glucose. Samples were neutralized with 50 μL 2 M NaOH, and glucose was 
determined using the D-glucose kit. For visualization of LB degradation product, degradation 
reactions were allowed to proceed as above, and the reactions were centrifuged to pellet 
undigested substrate. After 75 μL of the supernatant was removed, the remaining 25 μL was 
resuspended, and 5 μL was stained with 5 μL 20× Lugol's iodine, mounted on glass slides with a 
glass coverslip, and visualized using a Nikon Eclipse E600 using DIC/Nomarski contrast and an 
AxioCam MRm camera at 100x. In addition to the D-glucose kit, the absorbance-based PGO 
assay (Sigma) was also used to quantify glucose in starch degradation assays.  
In vitro degradation of LBs in muscle homogenates was performed as follows: 300 mg of 
skeletal muscle from WT or laforin KO mice was pulverized over liquid N2 and homogenized in 
4 vol. degradation buffer. Homogenate was split into 2 × 500 μL aliquots, and 25 μg VAL-0417 
was spiked into one aliquot for a final concentration of 0.05 mg/ml. Samples were incubated on a 
rotator overnight at room temperature and the next morning centrifuged for 5 min at 16,000×g. 
The supernatant was removed, and the pelleted material containing LBs was resuspended in 
degradation buffer and boiled for 30 min on a 95°C heat block to solubilize LBs. The boiled 
samples were clarified by centrifugation (16,000×g for 5 min) and 25 μL of supernatant was 
added to a microplate. 50 μL of 1×Lugol's iodine and 25 μL of water were added to samples, and 
absorbance was measured at 550 nm.  
 
Scanning electron microscopy  
Starch granules were incubated with enzymes in degradation buffer overnight while agitating, 
washed in 1mL 100% ethanol, dried in a vacuum centrifuge, and applied to carbon tape on a pin 
mount. Samples were coated with gold and platinum to improve sample conductivity, and 
visualized under high vacuum at 2 kV using an FEI Quanta 250 field emission scanning electron 
microscope. Washing in ethanol, drying, and manual application to carbon tape did not yield 
satisfactory results for LB visualization (Fig. S4), so alternatively, diluted LBs were applied to a 
 24 
mounted silicon wafer, lyophilized, coated in gold and platinum, and visualized at 2 kV with the 
FEI Quanta 250.  
 
Profiling of degradation product by HPAEC-PAD 
80 μg of LBs were treated with 2.67 μg of VAL-0417 in degradation buffer to a final 
concentration of LBs at 1 μg/μL. The enzymatic reactions were done at 37°C in triplicates. 20 μL 
samples were removed at 24, 48, 72 hour intervals followed by addition of 2.67 μg of VAL-
0417. The aliquots were stored at -20°C until they were run. The final reactions were continued 
at 37°C for total of 168 hours. All samples were profiled using CarboPac PA-100 column 
(Thermo-Dionex, 4 x 250 mm) and detected with PAD detector. 5 μL of samples from each time 
point (corresponding to 5 μg LBs total) were injected on the column. Blank LBs and degradation 
buffer were injected as controls. Glucose and maltose in the degradation reactions were 
quantified by comparing with standards of known amount (Fig. S7A). 5 μg Maltrin100 was also 
included as a standard for oligosaccharide profiling (Fig. S7E).  
 
Cell culture studies of VAL-0417 uptake  
Protein Phosphatase 1 (PP1) stimulates glycogen synthesis by both dephosphorylating and 
activating glycogen synthase and inhibiting glycogen phosphorylase, the primary enzymes 
catalyzing glycogen synthesis and degradation, respectively (Newgard et al., 2000). Protein 
targeting to glycogen (PTG) is a regulatory, glycogen-targeting subunit of PP1 that stimulates 
glycogen synthesis when overexpressed in cell lines (Printen et al., 1997; Worby et al., 2008). 
Constitutive overexpression of PTG in WT mice has been shown to lead to cerebral 
polyglucosan accumulation in Epm2b-/- mice (Duran et al., 2014). We sought to design a cell 
line that accumulates polyglucosan like that which makes up LBs. 
  HEK293 cells (Graham et al., 1977) were co-transfected with plasmids pCDH-FLAG-PTG 
and pCDH-(HA)3-PP1Cα-GFP harboring mouse PTG and the human PP1Cα (catalytic alpha-
subunit of PP1) cDNAs, respectively. Mixed clones were selected for ~10 days in the presence 
of 1 μg/ml hygromycin and 0.2 mg/ml puromycin, expanded and stored in liquid N2. Analyses of 
protein expression and glycogen synthase activity ratio in the absence and presence of glucose-6-
phosphate indicated that both proteins were expressed, and the glycogen synthase activity ratio 
was increased 3-fold, from 0.02 in control cells to 0.06 in transfected cells.  Quantitation of the 
expression of PTG and PP1Cα is difficult because the basal levels are very low, undetectable 
under our conditions.    
 For quantitation of polysaccharide levels HEK293, HEK293-PTG/PP1Cα and 
Rat1fibroblasts (Skurat et al., 2000) were plated in 96-well plates at a density of 40,000 
cells/well. After 48 hr, media was changed and the next day, the cells were washed 3 times with 
PBS followed by overnight incubation at 40°C in 50 μL of 0.2 M sodium acetate pH 4.8 
containing 0.2% Triton and 0.3 mg/ml amyloglucosidase (Aspergillus niger; Sigma).  Identical 
cell cultures were lysed in 50 μL of in 0.2 M sodium acetate pH 4.8 containing 0.2% Triton for 
protein determination by the Bradford procedure.  
 After overnight digestion, polysaccharide was measured by transferring 40 μL samples to a 
new 96-well plate. A 160 μL reaction mixture consisting of 0.375 M ethanolamine pH7.6, 5 mM 
MgCl2, 1.12 mM NADP, 2.5 mM ATP and 0.2 Units of G6PDH (Roche Biochemicals 
10127655001) was added and OD340 nm was recorded.  Subsequently, 0.75 units of hexokinase 
(Roche 11426362001) were added, the reaction incubated at room temperature for 30 min and 
OD340 recorded again. Background absorbance was subtracted from sample absorbance and 
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glucose equivalents were determined based a digested glycogen standard curve. The engineered 
HEK293 line accumulated >30-fold more polysaccharide than the native HEK293 cells, and 
twice the level of normal glycogen found in Rat1 cells (Fig. S6).  
To determine the effect of VAL-0417 on polysaccharide degradation, cells were plated in 96-
well plates at a density of 40,000 cells/well, and after 4 days various concentrations of VAL-
0417 were added for 20 hr to fresh growth media. Cells were then washed 3 times with PBS, 
fixed for 7 min with 3.7% formaldehyde in 90% ethanol, washed again 3 times with PBS and 
polysaccharide content was determined by hydrolysis and glucose determination.  Statistical 
significance was assessed by using an unpaired Student t-test. 
For Western analyses, 20 μg of total cell lysates were separated on SDS-PAGE and protein 
transferred to nitrocellulose membranes that were probed with antibodies against human 
pancreatic α-amylase (AMY2A) and ENT2 followed by appropriate HRP-conjugated secondary 
antibodies and chemiluminescence.  
 
Enzyme-linked immunosorbent assay 
The capture antibody raised against the 3E10 Fab fragment was generated by Valerion 
Therapeutics (Concord, MA). Wells of a 96-well plate were incubated with 100 μL of capture 
antibody overnight (~16 hours) at a final concentration of 2 μg/ml in PBS. All incubations were 
done in a humidified chamber. Wells were then rinsed 3 times with 200 μL PBS followed by 
incubation for 1 hour with 200 μL of blocking solution (5% non-fat milk in PBS). Wells were 
then rinsed 3 times with 200 μL PBS. 100 μL of diluted tissue homogenates were added and 
incubated for 1 hour. Wells were then rinsed 3 times with 200 μL of Tris-buffered saline (TBS) 
and 100 μL of primary antibody (anti-AMY2A) in 5% non-fat milk and TBS was added and 
incubated for 1 hour. The wells were then washed (solution added and incubated for 5 minutes 
before being removed) 3 times with TBS. 100 μL of secondary antibody (anti-rabbit IgG, HRP-
linked) in 5% non-fat milk in TBS was added and incubated for 1 hour. Wells were then washed 
5 times with TBS. 100 μL of TMB substrate was added and a timer started. After the highest 
concentration of standard curve saturated or a pre-set time was met, the reaction was stopped by 
adding 100 μL of stopping solution (0.18% H2SO4). The plate was then read for absorbance at 
450 nm. 
 
In vivo mouse studies  
For each IM injection, 20 μL VAL-0417 (30 mg/ml; 0.6 mg per injection) or 20 μL PBS was 
injected into one gastrocnemius. For the IV injections, mice were pretreated intraperitoneally 
with diphenhydramine (15mg/kg) before each injection to prevent anaphylaxis. After the 
diphenhydramine, the mice where kept under a heat lamp for twenty minutes. A Mouse Tail 
Illuminator (BrainTree Scientific, Inc.) was used to restrain the mouse and an insulin 
syringe/needle was used to inject PBS or VAL-0417 into the dorsal tail vein. 100 μL of PBS was 
injected into IV control mice on days 1, 5, 8, and 13. For the IV treatment group, 100 μL of 30 
mg/ml VAL-0417 (3 mg total) was administered on days 1 and 5, 100 μL of 20 mg/ml VAL-
0417 (2 mg total) on day 8, and 130 uL of 23 mg/ml VAL- 0417 (3 mg total) on day 13. At the 
indicated time points post-injection(s), mice were euthanized by cervical dislocation and 
decapitation. Tissues were harvested, flash frozen, powdered over liquid N2 using Freezer/Mill 
Cryogenic Grinder (SPEX SamplePrep), and stored at -80°C. Powdered tissues were weighed, 
homogenized in assay buffer from the BioVision amylase assay kit and protein concentration 
was determined using the Pierce BCA Protein Assay Kit. For the ELISA assay, tissue 
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homogenates were diluted in PBS for a final concentration of 0.1 μg protein/μL in 100 μL. 
Diluted homogenates were added to 96-well plates for the ELISA utilizing a capture antibody 
binding the 3E10 Fab fragment and anti-AMY2A as the detection antibody. Polysaccharide 
content was determined using the Pflüger method.  
 IT and ICV studies were performed by Northern Biomedical Research, Inc. (Spring Lake, 
MI). Animals were anesthetized with a mixture of oxygen 0.5 to 1 L/min and isoflurane 1 to 5% 
prior to and during the catheter implantation procedure. The IT catheter attached to an osmotic 
pump was inserted at the cisterna magna and advanced caudally 2.5 cm to the lumbar region. The 
ICV cannula attached to an osmotic pump was inserted into the cerebral lateral ventricle and 
anchored VAL-0417 (30 mg/ml) or PBS was continuously administered via the IT catheter or 
ICV cannula for 3, 8 or 28 days (0.11 μL/hr). On the day following the last day of infusion, mice 
were euthanized by isofluorane/oxygen sedation and perfusion via the left cardiac ventricle with 
0.001% sodium nitrite in heparinized saline. For the 3- and 28- day experiments, brains were 
harvested, weighed, sectioned using a Rodent Brain Matrix (RBM-2000C, ASI Instruments) with 
2.0 mm coronal section slice intervals, flash frozen and stored at -80°C. Slices were directly 
homogenized in BioVision assay buffer using polypropylene pellet pestles in microcentrifuge 
tubes.  VAL-0417 levels and amylase activity were determined by ELISA and the BioVision 
assay and normalized to protein content. Protein and polysaccharide content were determined by 
BCA assay and the Pflüger method, respectively.  
For the 8-day ICV experiment, brains were weighed, separated into two hemispheres 
(longitudinal dissection) and each hemisphere was weighed. The right hemisphere was rinsed in 
PBS and submerged in 10% neutral buffered formalin (NBF) for approximately 48 hours at room 
temperature with periodic agitation. After approximately 48 hours, the 10% NBF was replaced 
with 70% ethanol and stored at room temperature. Staining was performed on 4-micron thick 
sections cut from formalin fixed paraffin embedded tissue.  Slides were deparaffinized and 
hydrated stepwise. Combination Periodic Acid-Schiff’s Stain staining was carried out on 4 µm 
sections, along with appropriate positive controls per standard protocols (Luna, 1968; Sheehan 
and Hrapchak, 1980). After staining, slides were scanned and analyzed and images were 
prepared using the HALO image analysis software (PerkinElmer). The left hemisphere was 
frozen in liquid nitrogen, pulverized using the Freezer/Mill Cryogenic Grinder, and the powdered 
tissue was stored at -80°C. Aliquots of pulverized tissue were weighed and resuspended in 
BioVision assay buffer for the ELISA, added directly to 30% KOH for polysaccharide 
determination via the Pflüger method, or used for metabolite extraction.  
 
GCMS metabolomics analysis 
20 mg pulverized mouse brain were extracted for polar metabolites using 1ml of ice cold 50% 
methanol. The polar fraction was transferred to a V-shaped GCMS glass vial and dried using a 
SpeedVac (Thermo) followed by derivatization and GCMS analysis. Dried polar samples were 
derivatized by sequential addition of 20 mg/ml methoxylamine hydrochloride in pyridine then 
the trimethylsilylating agent N-methyl-N- trimethylsilyl-trifluoroacetamide (MSTFA) with brief 
agitation in between at 37 oC. After cooling, the derivatized mixture analyzed by GCMS. GCMS 
protocols were similar to those described previously (Jung and Oh, 2015; MacRae et al., 2012), 
except a modified temperature gradient was used for GC: Initial temperature was 130° C, held 
for 4 minutes, rising at 6° C/minutes to 243° C, rising at 60° C/minutes to 280° C, held for 2 
minutes. The electron ionization (EI) energy was set to 70 eV. Scan (m/z:50-800) and full scan 
mode were used for metabolomics analysis. Mass spectra were translated to relative metabolite 
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abundance using the Automated Mass Spectral Deconvolution and Identification System 
(AMDIS) software matched to the FiehnLib metabolomics library (available through Agilent) for 
retention time and fragmentation pattern matching with a confidence score of >80 (Fiehn, 2016; 
Fiehn et al., 2000; Kind et al., 2009). For mono-, di- and trisaccharide quantitation, molecular 
ions 319 (mono) with a retention time between 17.5 and 18.5 min were used, 361 (di) with a 
retention time between 24.5 and 26.5 min were used, and 361 (tri) with a retention time between 
31 and 32 min were used. Values were first normalized to norvaline within the sample to account 
for sample loss, then DNA-derived thymine to represent input volume.  
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
For quantification of LB size and distribution, individual LBs in 3-5 micrographs were 
measured manually using ImageJ and a frequency distribution was calculated for LBs from each 
tissue type using Prism software (GraphPad) and a bin width of 1 μm. Only clearly delineated 
LBs were measured; clumps and dust-like particles were excluded. Statistical significance of 
polysaccharide reduction in cultured cells and animal tissues was determined using the Prism 
software (GraphPad). A t-test was used when two groups were present, and two-way analysis of 
variation (ANOVA) was used for comparing three groups or more. Data are represented as mean 
± standard error of the mean (SE) or standard deviation (SD), as indicated. For in vivo 
experiments, the numbers of animals (n) per group are indicated. PCA and clustering heatmap 
analysis were performed using the ClustVis package for R (available through Github, 
https://github.com/taunometsalu/ClustVis) (Metsalu and Vilo, 2015). All available metabolomics 
data points were used for multivariate analysis.  
 
SUPPLEMENTAL INFORMATION 
 
Supplementary Figures. Figures S1-S11.  
 
Table S1. List of all metabolites and their relative abundance per animal utilized in PCA and 
heatmap analyses, related to Figure 7. 
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Figures:  
 
 
Fig. 1. The antibody-enzyme fusion VAL-0417 degrades starch, a proxy for LBs. (A) 
Degradation of starch by a panel of amylases. 1 mg of starch was incubated with 5 µg of amylase 
overnight with constant agitation, then soluble and insoluble fractions were separated by 
centrifugation. Degradation product in the soluble fractions was quantified by measuring glucose 
equivalents (i.e. glucan). Reactions were performed in triplicate and data shown are means ± SD. 
(B) Schematic representation of VAL-0417. The gene encoding the human IgG1 Fab heavy 
chain fragment (H) was fused to AMY2A, encoding human pancreatic α-amylase, and 
coexpressed with the gene encoding the human light chain (L) in HEK293-6E cells. Heavy and 
light chain signal peptides were included to facilitate proper folding and assembly of the Fab 
fragment. The predicted molecular weight of each polypeptide is shown. (C) Purity of VAL-
0417 assessed by reducing (+BME) and nonreducing (-BME) SDS-PAGE. (D) Chemical 
structure of the α-amylase-specific substrate E-G7-pNP. Reducing (inner) and non-reducing 
(outer) ends of the substrate are displayed. (E) Degradation of 1 mg starch after a 2-hour 
incubation with increasing amounts of VAL-0417, expressed as glucan released in the soluble 
fraction. Mean ±SD of triplicate reactions are shown. (F) Scanning electron micrographs of 
starch granules in the absence of treatment and after overnight treatment with VAL-0417. 
Samples were visualized at 2kV by an FE Quanta 250 scanning electron microscope. 
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Fig. 2. A novel protocol for isolating native LBs from LD mice. (A) LB purification scheme. (B) 
Polysaccharide was purified at different steps in the protocol via the Pflüger method and 
quantitated via glucose measurement following hydrolysis. Initial tissue weights and total 
polysaccharide at each step are shown. (C) Polysaccharide yields normalized to tissue weight. 
Triplicate samples were removed from each fraction and each measured in triplicate. Mean ±SD 
are shown. (D) Phosphate content of LBs from skeletal muscle and normal rabbit muscle 
glycogen. Mean ±SD of triplicate measurements are shown. (E) Normalized iodine spectra of 
purified LBs compared to commercial liver glycogen and amylopectin. Spectra shown are an 
average of 3 replicates. (F) Brain, (G) heart, and (H) skeletal muscle LBs stained with Lugol's 
solution and visualized using a Zeiss Axioimager Z1. 
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Fig. 3. Scanning electron micrographs of isolated LBs. Scanning electron micrographs of LBs 
purified from brain (A), heart (B), and skeletal muscle (C) displayed using the same scale. LBs 
from skeletal muscle are also shown at a higher magnification (D). Samples were visualized at 2 
kV using an FE Quanta 250.  
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Fig. 4. VAL-0417 degrades LBs in vitro. (A) Degradation of 50 µg LBs from different tissues 
after overnight incubation with 0, 1, or 10 µg VAL-0417. (B) LBs from different tissues after 
overnight incubation +/- 10 µg VAL-0417. Insoluble fractions were resuspended post-
degradation, stained with Lugol's solution, and visualized using a Nikon Eclipse E600. (C) 
Iodine absorbance in pellet fractions after incubation of WT and Epm2a-/- skeletal muscle 
homogenates +/- 25 µg VAL-0417. In (A), (C), and (E) mean ± SD of triplicates are shown. (D) 
HPAEC-PAD chromatogram of degradation product after incubation with VAL-0417 for 168 
hours. Peak identities were determined based on the elution profile of degradation buffer and 
glucan standards. The chromatogram is representative of triplicate experiments, and 
glucose/maltose quantification from the replicates is shown in (E). (E) Quantification of glucose 
and maltose at various time points throughout the degradation reaction of LBs with VAL-0417. 
Product released are expressed as a percentage of total LBs.  
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Fig. 5. VAL-0417 uptake and polysaccharide reduction in cell culture. (A) Rat1 cells and 
HEK293 cells stably expressing PTG and PP1Cα after 20-hour treatment with increasing 
concentrations of VAL-0417. VAL-0417 levels were assessed by Western blotting using an anti-
AMY2A antibody. ENT2 levels were also quantified by Western blotting. (B) Polysaccharide 
levels per well in Rat1 and HEK293-PTG/PP1Cα cells after 20-hour treatment with VAL-0417. 
Data shown are a mean of 4 measurements ± SE. Statistical significance determined by t-test is 
indicated: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.  
  
 35 
 
 
 
Fig. 6. VAL-0417 reduces LB load in vivo after intramuscular (IM) or intravenous (IV) injection. 
(A) Biodistribution of VAL-0417 levels determined by sandwich ELISA after IM injection of 
WT mice with PBS or 0.6 mg VAL-0417. (B) Quantification of polysaccharide in the injected 
gastrocnemii of WT and Epm2a-/- mice after 3 IM injections of PBS or VAL-0417 administered 
over the course of one week. (C) Quantification of polysaccharide in the heart of WT and 
Epm2a-/- mice after 4 IV injections of PBS or VAL-0417 administered over a two-week period. 
Polysaccharides in (B) and (C) were isolated via the Pflüger method and quantified by glucose 
measurement assays following hydrolysis. (D, E) PAS-stained heart tissue of WT (D) and 
Epm2a-/- (E) mice after IV treatment regimen. Intensely staining PAS-positive deposits are LBs 
(purple). Tissues were counterstained with hemotoxylin (blue).  
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Fig. 7. VAL-0417 reduces LB load and reverses metabolic derangement in vivo after continuous 
ICV infusion. (A) Representative photograph of six 2.0 mm coronal sections. Evans blue dye 
was injected through the cannula into the lateral ventricle to verify its location within slice 2. (B) 
Polysaccharide content normalized to protein content in Epm2a-/- brain slices after 28 days of 
continuous ICV infusion of VAL-0417 or PBS. (C) Total brain polysaccharide normalized to 
tissue weight from untreated, PBS treated, and VAL-0417 treated Epm2a-/- mice after 8-day 
ICV infusion. (D) VAL-0417 levels in PBS and VAL-0417 treated animals determined by 
ELISA. In (B), (C), and (D) at least three technical replicates were performed for each isolated 
slice to determine an average per slice per animal, and data shown are the mean from each 
treatment group ± SE. The numbers of animals in each treatment group (n) are shown. Statistical 
significance is indicated as determined by ANOVA (B) and t-test (C):  * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001. (E) PAS-stained brain slices of PBS and VAL-0417 treated Epm2a-/- mice after 
8-day ICV infusion. LB deposits appear purple; tissue was counterstained with hemotoxylin 
(blue). (F) Two-dimensional principle component (PC) plots for polar metabolites of PBS and 
VAL-0417 treated Epma2-/- animals (orange and blue dots, respectively) after 8-day infusion 
compared to untreated WT and Epm2a-/- controls (black and red dots, respectively). There is a 
clear separation between the groups, which has been shaded accordingly. (G) Relative abundance 
of mono-, di- and tri-saccharides determined by GCMS from untreated WT and Epm2a-/- mice 
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and also Epm2a-/- mice treated with PBS or VAL-0417. Statistical significance was determined 
by two-way ANOVA: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
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Supplementary Material 
 
Materials and Methods 
 
Expression and purification of VAL-0417  
The cDNA encoding the human IgG1 Fab-linker-AMY2A heavy chain and light chain were 
synthetically produced with codon optimization for mammalian cell expression and cloned into 
pTT5. HEK293 cells expressing a truncated variant of the Epstein Barr Virus nuclear antigen 1 
(HEK293-6E) increase the volumetric yield of monoclonal antibodies and fragments and were 
used for VAL-0417 expression (Jager et al., 2013).  2 1L cultures of HEK293-6E cells in 2L 
shake flasks were transfected with 1 mg of total plasmid DNA/L (1:1 ratio heavy chain:light 
chain) culture using PolyPlus linear Q-PEI at a 1:1.5 (w/v) DNA:PEI ratio. Culture parameters 
were monitored using a ViCell XR (Beckman Coulter) for density and viability. Culture was 
harvested 5 days post transfection via centrifugation for 5 minutes at 1000×g. The conditioned 
culture supernatant was clarified by centrifugation for 30 minutes at 9300×g.  
 Pre-packed CaptureSelect IgG-CH1 affinity columns (Fisher) were equilibrated in PBS (pH 
7.2). VAL-0417 from 2 L of exhausted supernatant was top-loaded onto affinity columns (2 x 1 
mL columns in tandem) at 4°C overnight. The column was washed with approximately 15 
column volumes (CV) of PBS, 15 CV of buffer B (1×PBS with 500 mM NaCl, pH 7.2) and 15 
CV of PBS. The resin-bound fusion protein was eluted with 10 CV of Buffer C (30 mM NaOAc, 
pH 3.5-3.6), collecting the protein in 1 mL fractions diluted in 1/10th volume Buffer D (3 M 
NaAcetate pH~9.0) to neutralize. To minimize the elution volume, elution was paused for 
several minutes between each fraction collected. Fractions were analyzed by A280 prior to 
pooling fractions and pools were analyzed by SDS-PAGE. VAL-0417 remained in the non-
bound pool from the first affinity chromatography pass. The above procedure was repeated to 
capture remaining fusion protein. The affinity pools were combined prior to dialysis. The 
combined CaptureSelect IgG-CH1 affinity pool (18 mL) was dialyzed against 3 x 1 L of dialysis 
buffer (20 mM Histidine, 150 mM NaCl, pH 6.5) at 4°C. The dialyzed pool was concentrated to 
1 mg/mL using a VivaSpin 20 (10K MWCO, PES membrane) centrifugal device prior to final 
analysis and storage at -80°C. Purified Fab-AMY was analyzed by size exclusion 
chromatography (Agilent HP1100) showing a single peak before and after a freeze-thaw cycle, 
indicative of a single, stable species.  
 
Pflüger method for polysaccharide isolation  
Glycogen and polyglucosan from Epm2a-/- and Epm2b-/- mice have been purified and 
characterized by multiple groups using the Pflüger method, but a chaotropic salt must be added 
to enhance the efficiency of polyglucosan precipitation (Tagliabracci et al., 2008). We wanted to 
clarify that under native conditions, and prior to the Pflüger treatment, LBs in Epm2a-/- and 
Epm2b-/- tissues are intact, micron-sized structures (Fig. 2 F to H, Fig. 3, and fig. S5B). Pflüger 
treatment converts the LBs to much smaller polysaccharide molecules that are on the same 
nanometer scale as glycogen molecules, but they contain elevated phosphate and an altered chain 
length distribution (Nitschke et al., 2013; Tagliabracci et al., 2008). Thus, the term "LB" refers to 
the native, micron-sized polysaccharide-containing structures found in LD tissues, and 
"polyglucosan" refers to the abnormal polysaccharide comprising LBs, which is released with 
Pflüger treatment.  
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 The Pflüger method is direct and very sensitive and was used to track polysaccharide yield 
throughout the native LB purifications or to detect polysaccharide content of mouse tissues for in 
vivo studies. Aliquots from native LB purifications or tissue homogenates were added to 10 vol. 
30% KOH, boiled for 2 hours, and allowed to cool. 2 vol. cold ethanol and 10 µL LiCl (1 M or 
20 mM) were added, and samples were precipitated overnight at -20°C. Precipitated samples 
were centrifuged for 10 min at 16,000×g at 4°C, the supernatant was removed, and the 
polysaccharide pellet was resuspended in water. Two additional precipitations with cold ethanol 
and LiCl were carried out, each for 1-2 hours at -20°C. The final pellet was washed in cold 
ethanol and resuspended with vortexing in 200 µL water. Polysaccharide was quantified by 
overnight hydrolysis with amyloglucosidase from Aspergillus niger (Sigma) and glucose 
determination was carried out using the R Biopharm Inc. D-glucose kit (Fisher). Fluorescence 
(ex340/em445) rather than absorbance of the NADPH product (stoichiometric to glucose) was 
measured for higher sensitivity.  
 
Separation of glycogen and LBs in native LB purification  
After the initial centrifugation step in the LB purification, a fraction of the heart and muscle 
glycogen was consistently present in the supernatant (Fig. 2, B and C). In our preliminary 
purifications, we found that the homogenate and pellet fractions stained brown with Lugol's 
iodine after boiling, as did the final LBs and amylopectin, but the supernatants stained yellow 
like glycogen (fig. S2A). We also stained the Pflüger-purified polysaccharide fractions from our 
large-scale preparations in Figure 2C with Lugol's iodine, measured absorbance at 550 nm, and 
compared the values to the polysaccharide concentrations determined by hydrolysis and glucose 
measurement (fig. S2B). While the polysaccharide from the supernatant did not absorb at 550 
nm, polysaccharide from the pellet, filtrate and final fractions produced a high absorbance 
relative to concentration. Polysaccharide in the homogenate fraction was less absorbent relative 
to concentration. These data indicate that the polysaccharide in the heart and muscle tissue 
homogenates included both glycogen and polyglucosan (in the form of LBs), that were separated 
into supernatant and pellet fractions after low-speed centrifugation. No polysaccharide was 
detected in the supernatant fractions from brain (Fig. 2, B and C). This result is consistent with 
the observation that in normal mice, glycogen levels are lower in brain than in other tissues in 
part due to its rapid catabolism after euthanasia (Oe et al., 2016). 
 
Iodine-based measurements 
Lugol's iodine was prepared as a 20×stock (1.5 M KI and 100 mM I2). To detect LBs in 
preliminary purifications, 50 µL samples from purification fractions were boiled for 15 minutes 
on a 95°C heat block, clarified by centrifugation (16,000×g for 1 min), and 35 µL of the 
supernatant was added to 50 µL 1×Lugol's iodine and 15 µL water for 100 µL total (fig. S2A). 
To analyze iodine absorbance of polysaccharide from LB purifications, Pflüger-isolated 
polyglucosan fractions were added to 50 µL 1×Lugol's iodine for 100 µL total and absorbance 
was measured at 550 nm. Absorbance was graphed alongside glucose-based concentrations to 
illustrate the fractionation of polyglucosan and glycogen into supernatant and pellet fractions, 
respectively (fig. S2B). For spectral scans, 50 µg LBs, rabbit liver glycogen (Sigma), and potato 
amylopectin (Sigma) were solubilized by boiling for 30 min and added to 50 µL 1×Lugol's 
iodine for 100 µL total. Absorbance scans were performed at 400-800 nm in 10 nm steps. 
 
Determination of LB phosphate content 
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Muscle glycogen and LBs contain covalent phosphate linked to the C2, C3, and C6 hydroxyls of 
glucose moieties, and the relative ratios of these modifications are equivalent (DePaoli-Roach et 
al., 2014; Nitschke et al., 2013; Tagliabracci et al., 2011). Boiling in mild HCl hydrolyzes 
glycosidic bonds and releases the acid-labile C2- and C3-linked phosphate leaving C6 
phosphoesters intact in the form of glucose-6-phosphate (Nitschke et al., 2013). Thus, inorganic 
phosphate after mild acid hydrolysis represents only C2- and C3-linked phosphate, i.e. two-thirds 
of total phosphate. To determine phosphate content, skeletal muscle LBs were boiled for 2 hours 
at 95°C in 1 M HCl. Reactions were neutralized with NaOH and inorganic phosphate in the 
sample was determined using the Pi ColorLock Gold Phosphate Detection System (Innova 
Biosciences). Glycogen purified from rabbit skeletal muscle as previously described was used as 
a positive control, and the levels of phosphate detected using our method are consistent with two-
thirds of published total phosphate levels (DePaoli-Roach et al., 2014).  
 
Generation of HEK293-PTG/PP1Cα cells and polysaccharide quantitation 
Protein Phosphatase 1 (PP1) stimulates glycogen synthesis by both dephosphorylating and 
activating glycogen synthase and inhibiting glycogen phosphorylase, the primary enzymes 
catalyzing glycogen synthesis and degradation, respectively (Newgard et al., 2000). Protein 
targeting to glycogen (PTG) is a regulatory, glycogen-targeting subunit of PP1 that stimulates 
glycogen synthesis when overexpressed in cell lines (Printen et al., 1997; Worby et al., 2008). 
Constitutive overexpression of PTG in WT mice has been shown to lead to cerebral 
polyglucosan accumulation in Epm2b-/- mice (Duran et al., 2014). We sought to design a cell 
line that accumulates polyglucosan like that which makes up LBs. 
  HEK293 cells (Graham et al., 1977) were co-transfected with plasmids pCDH-FLAG-PTG 
and pCDH-(HA)3-PP1Cα-GFP harboring mouse PTG and the human PP1Cα (catalytic alpha-
subunit of PP1) cDNAs, respectively. Mixed clones were selected for ~10 days in the presence 
of 1 µg/ml hygromycin and 0.2 mg/ml puromycin, expanded and stored in liquid N2. Analyses of 
protein expression and glycogen synthase activity ratio in the absence and presence of glucose-6-
phosphate indicated that both proteins were expressed, and the glycogen synthase activity ratio 
was increased 3-fold, from 0.02 in control cells to 0.06 in transfected cells.  Quantitation of the 
expression of PTG and PP1Cα is difficult because the basal levels are very low, undetectable 
under our conditions.    
 For quantitation of polysaccharide levels HEK293, HEK293-PTG/PP1Cα and 
Rat1fibroblasts were plated in 96-well plates at a density of 40,000 cells/well. After 48 hr, media 
was changed and the next day, the cells were washed 3 times with PBS followed by overnight 
incubation at 40°C in 50 µL of 0.2 M sodium acetate pH 4.8 containing 0.2% Triton and 0.3 
mg/ml amyloglucosidase (Aspergillus niger; Sigma).  Identical cell cultures were lysed in 50 µL 
of in 0.2 M sodium acetate pH 4.8 containing 0.2% Triton for protein determination by the 
Bradford procedure.  
 After overnight digestion, polysaccharide was measured by transferring 40 µL samples to a 
new 96-well plate. A 160 µL reaction mixture consisting of 0.375 M ethanolamine pH7.6, 5 mM 
MgCl2, 1.12 mM NADP, 2.5 mM ATP and 0.2 Units of G6PDH (Roche Biochemicals 
10127655001) was added and OD340 nm was recorded.  Subsequently, 0.75 units of hexokinase 
(Roche 11426362001) were added, the reaction incubated at room temperature for 30 min and 
OD340 recorded again. Background absorbance was subtracted from sample absorbance and 
glucose equivalents were determined based a digested glycogen standard curve. The engineered 
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HEK293 line accumulated >30-fold more polysaccharide than the native HEK293 cells, and 
twice the level of normal glycogen found in Rat1 cells (fig. S6).  
 
Enzyme-linked immunosorbent assay (ELISA) 
The capture antibody raised against the 3E10 Fab fragment was generated by Valerion 
Therapeutics (Concord, MA). Wells of a 96-well plate were incubated with 100 µL of capture 
antibody overnight (~16 hours) at a final concentration of 2 µg/ml in PBS. All incubations were 
done in a humidified chamber. Wells were then rinsed 3 times with 200 µL PBS followed by 
incubation for 1 hour with 200 µL of blocking solution (5% non-fat milk in PBS). Wells were 
then rinsed 3 times with 200 µL PBS. 100 µL of diluted tissue homogenates were added and 
incubated for 1 hour. Wells were then rinsed 3 times with 200 µL of Tris-buffered saline (TBS) 
and 100 µL of primary antibody (anti-AMY2A, Abcam #ab21156) in 5% non-fat milk and TBS 
was added and incubated for 1 hour. The wells were then washed (solution added and incubated 
for 5 minutes before being removed) 3 times with TBS. 100 µL of secondary antibody (anti-
rabbit IgG, HRP-linked, Cell Signaling Technology 7074) in 5% non-fat milk in TBS was added 
and incubated for 1 hour. Wells were then washed 5 times with TBS. 100 µL of TMB substrate 
(ThermoFisher N301) was added and a timer started. After the highest concentration of standard 
curve saturated or a pre-set time was met, the reaction was stopped by adding 100 µL of stopping 
solution (0.18% H2SO4). The plate was then read for absorbance at 450 nm. 
 
Supplementary Figures 
 
 
Fig. S1. Starch degradation with different VAL-0417:starch ratios. (A) Degradation with low 
ratio (10 µg VAL-0417, 1 mg starch). (B) Degradation with high ratio (10 µg VAL-0417, 100 µg 
starch).  
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Fig. S2. Iodine staining of LB purification fractions. (A) 50 µL samples were removed from 
homogenate, supernatant, and pellet fractions during preliminary LB purifications from skeletal 
muscle, boiled for 30 minutes, and clarified by centrifugation. 30 µL of the clarified sample was 
diluted with 15 µL water and stained with 50 µL 1x Lugol's solution in a microplate. Commercial 
liver glycogen and amylopectin were also stained as controls. (B) Concentration vs. iodine 
absorbance at 550 nm of Pflüger-isolated polysaccharide from skeletal muscle at each step of the 
purification scheme.  
 
 
 
Fig. S3. Size distribution of LBs purified from different tissues and appearance of dust-like 
particles. Frequency distribution of LBs from each tissue type: (A) brain (total count: 473), (B) 
heart (total count: 247), and (C) skeletal muscle (total count: 252). Two fields of view from (D) 
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brain and heart (E) LB preparations containing numerous dust-like particles are shown. Black 
boxes indicate areas that have been magnified and are labeled correspondingly (e1, e2, etc.). 
Occasionally very large bodies were observed (10-20 µm). They were difficult to distinguish 
from tightly packed clumps, so they were excluded from the size distribution histograms.   
 
 
Fig. S4. Scanning electron micrographs of LBs from brain, heart and skeletal muscle, washed in 
ethanol, dried, and applied to carbon tape. Samples were visualized at 2kV under high vacuum 
by an FE Quanta 250.  
 
 
 
Fig. S5. Soluble fractions of untreated and treated brain LBs (BrLBs) after degradation reactions. 
Samples from the soluble fractions and total reactions were stained with Lugol's solution and 
visualized using a Zeiss Axioimager Z1. 
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Fig. S6. Purification of LBs from skeletal muscle of 12-month-old Epm2b-/- mice. (A) LB 
purification yields. Mean ± SD of triplicate measurements are shown. (B) Epm2b-/- LBs stained 
with Lugol's solution and visualized by light microscopy. (C) Comparison of size distribution of 
skeletal muscle LBs from Epm2a-/- and Epm2b-/- mice. (D) Normalized iodine spectra of 
Epm2b-/- and Epm2a-/- skeletal muscle LBs. The spectral data are an average of 3 replicates.  
 
 
 
Fig. S7. HPAEC-PAD chromatograms of control samples and additional time points from LB 
degradation with VAL-0417. (A) Overlay of control chromatograms: degradation buffer only 
(black line), LBs only (red line), and a mixture of 1 µg glucose and 1 µg maltose standards for 
quantitation (blue line). A small amount of maltose and low molecular weight oligosaccharides 
were detected in the LB control. Additional time points from the 168 hour LB degradation 
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experiment with VAL-0417: (B) 24 hours, (C) 48 hours, and (D) 72 hours. Each chromatogram 
is representative of triplicate chromatograms. Small shifts in retention time (≤1 min) are typical 
between HPAEC-PAD runs. (E) Maltrin100, a mixture of low molecular weight 
oligosaccharides, was used as a standard for verifying degrees of polymerization (DP), i.e. 
number of glucose units.  
 
 
Fig. S8. Polysaccharide levels relative to protein concentration in three cell lines: Rat1, HEK293, 
and HEK293 stably expressing PTG and PP1Cα. Data are expressed as the mean of 12 replicates 
± SE.  
 
 
 
Fig. S9. Comparison of intrathecal (IT) versus intracerebroventricular (ICV) routes of 
administration in WT mice. (A) Distribution of VAL-0417 levels using the sandwich ELISA in 
PBS- and VAL-0417-treated WT brain slices after intrathecal (IT) or intracerebroventricular 
(ICV) infusion. (B) Distribution of VAL-0417 activity in the same slices measured using the 
BioVision amylase activity assay. Data shown are a mean of 3 measurements ± SE. 
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Fig. S10. Regional distribution of LB load in PBS and VAL-0417 treated Epm2a-/- (KO) 
animals compared to untreated WT and Epm2a-/- controls. PAS-stained slides were 
counterstained with hematoxylin (blue). LBs appear as PAS+ inclusions (bright purple). Slides 
were scanned and images were prepared using the HALO software (PerkinElmer). The left 
column represents the entire slice at low magnification; the other columns show individual 
regions at higher magnification and are labeled accordingly. Brain slices are representative of all 
animals analyzed for each group.  
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Fig. S11. Clustering heat map analysis illustrating the similarities in metabolite profiles between 
untreated WT and Epm2a-/- mice treated with VAL-0417 compared to PBS treated Epm2a-/- 
(KO) mice. Each row represents a metabolite, while each column represents an individual 
mouse. Colors indicate the magnitude of the difference between groups (log2 transformed 
relative abundance). The PBS-treated Epm2a-/- group was omitted to prevent confounding the 
groups. 
 
